

Index

a

- a emitters 422
- A-DOXO-HYD 777, 778
- A121 human ovarian tumor xenograft 1348
- $\alpha 2$ -macroglobulin 65
- AAG ($\alpha 1$ -acid glycoprotein) 1341
- AAV (adeno-associated virus) 1426, 1433
- AB.Fab fragments 109
- ABC (ATP-binding cassette) transporters 1493, 1494
 - inhibition, 1497
- ABD (albumin-binding domain) 107
- aberrant branching 693
- ablation 971
 - radiofrequency tumor 971
 - thermal 898
- ablative therapy
 - local 1521
- absorption, distribution, metabolism, and excretion (ADME) 1173, 1174
- AcBut hydrazone linker 112
- accessible vascular targets
 - mapping 430
- accumulation 1263
 - differential 1263
 - maytansinoid metabolites 391
 - nanocarriers 991
- ACE (angiotensin II-converting enzyme) 79
- acetals
 - trimethoxybenzylidene 1112
- acetamide functionality 73
- $\alpha 1$ -acid glycoprotein (AAG) 1341
- acid-activated PEG–drug conjugates 651
- acid-cleavable linkages 1103
- acid-labile hydrazone linker 103, 261
- acid-sensitive conjugates 772, 1536
- acid-sensitive linkages 5, 738
 - acid-sensitive linkers 24
 - acid-treated SWNTs 1175
 - acidic intracellular compartments 92
 - acidification
 - progressive 991
 - acidity
 - extracellular 1100
 - acidosis 53, 55
 - acrylamide
 - PEG 19
 - acrylic copolymers 1072
 - activated carboxy groups 1312
 - activation 989
 - AMCs 385, 389
 - biocatalytic 564
 - endothelial cells 591
 - external 1001
 - heat 1001
 - innate enzymes 1000
 - lysosomal 387
 - magnetic field 1006
 - oxidative 569
 - pH-dependent 569
 - photochemical 572
 - protease-dependent 1203
 - reductive 566
 - tumor-intrinsic stimuli 994
 - tumor-specific 564
 - ultrasound 1005
 - UV/IR 1003
 - active targeting 1057
 - CPPs 1205
 - platinum complexes 1612
 - SPIO particles 232
 - activity
 - SAR 19
 - actual delivery
 - uniformity 989

- acute lymphoblastic leukemia (ALL) 3
- acute lymphocytic leukemia (ALL) 105
- acute myeloid leukemia (AML) 96
- acyclization-based SIL 556
- acyl hydrazone-based conjugates 1299
- acyl tail dynamics
 - lipid 999
- adaptors
 - chemical 573
- ADC (apparent diffusion coefficient) 35, 54
- ADCC (antibody-dependent cellular cytotoxicity) 47, 292
- ADCs 108
- addition
 - Michael-type 559
- adducts
 - platinum–DNA 1035
- adeno-associated virus (AAV) 1426, 1433
- adenocarcinomas 1457
- adenovirus serotype 5 (Ad5) 1500
- adenoviruses 1392, 1400
 - oncolytic 1431
- ADEPT (antibody-directed enzyme prodrug therapy) 6, 16, 17, 34, 951
 - two-phase clinical trials 25
- adhesion molecule
 - epithelial cell 960
- adjuvant bisphosphate therapy 807
- administration 951
 - antibody-targeted liposomal drugs 951
 - combination chemotherapy 1022
- adrenocortical tumors
 - imaging 279
- AEC 18
- aerosolized liposomal paclitaxel 970
- AEZS-108 1235
- affinity
 - antibodies 21
- AFM13 469
- agents 1013
 - alkylating 34
 - amphipathic 1041
 - anti-MDR 1026
 - antiangiogenic 599
 - anticancer 45, 747, 763
 - antineoplastic 276
 - bifunctional chelating 92
 - chain transfer 266
 - chemically incompatible 1026
 - complexation 253
 - contrast 276, 1063
 - conventional anticancer 7
 - DNA-damaging 94
 - hydrophobic 1040
 - intravenously injected 328
 - microtubule-stabilizing 24
 - molecularly targeted 808
 - NO-releasing 78
 - radioimmunoscintigraphy 417
 - radionuclide delivery 423
 - reactive 1033
 - surface stabilizing 1041
 - therapeutic 443
- aggregation
 - liposomes 1005
- aglycone functionality
 - enediynes 95
- AGM (aminogluthetimine) 820
- AIDS-related Kaposi's sarcoma 919, 922
- AIF (apoptosis-inducing factor) 1453, 1470
- alanine transaminase 1542
- albondin 792
- albumin 747, 1099
 - bovine serum 566, 1123
 - carrier 786
 - cationized 1501
 - CBSA 1138, 1504
 - cross-linked matrix 1136
 - drug conjugates 772
 - Evans blue– 73
 - human serum 750, 862, 1133, 1323
 - lactosaminated 1532
 - microspheres 761
 - mouse serum 90
 - nab technologies 895, 1136
 - nanoparticles 895, 1133, 1150
 - serum 85
 - synthetic approaches 759
 - transcytosis 1134
 - zzz 763
- albumin-based nanoparticles
 - clinical studies 1152
- albumin-binding domain (ABD) 107
- albumin-conjugated PEGylated nanoparticles
 - cationic 1149
- alemtuzumab 292
- alendronate (ALN) 823, 825
- alginate–drug conjugates 730
- aliphatic anchors 1043
- aliphatic systems
 - releasable PEG linkers 649
- alkylating agents 34
- alkylating lysines 298
- alkylation
 - reductive 633
- alkylator
 - DNA 1336
- ALL (acute lymphoblastic leukemia) 3

- ALL (acute lymphocytic leukemia) 105, 107
- alternative scaffolds 431
- amides 1219
 - amide/amino-derived linkages 646
 - aromatic 1340
 - spontaneous ring-closure 557
- amino acids 12
 - ω -amino fatty acids 1249
 - metabolism 37
 - transport imaging 257
 - zwitterionic residue 77
- amino groups
 - lysine 1578
- aminoacyl-tRNAs 1459
- aminogluthetimine (AGM) 820
- aminolysis 258
- aminopeptidase P2 (APP2) 342
- aminopolysaccharides 717
- amiRNA 1421
- AML (acute myeloid leukemia) 400
- amlodipine 1026
- ammonia ligands 1607
- amphipathic drugs 909
- amphipathic peptides
 - Pep-3 1197
- amphipathic surface stabilizing agents 1041
- amphiphilic block copolymers 1103
- amphiphilic polymers 627
 - self-assembly 1078
- AN-152 1235
 - chromophore-labeled 1227
 - fluorophore-labeled 1227
 - structure 1224
- AN-162 1239
- AN-238 1238
- analysis 1283
 - analytical completeness 337, 338
 - biodistribution 343
 - retro-synthetic 1288
 - western 339
- anastomosis
 - vessel 591
- anatomic information
 - coregistration 282
- anatomy of BBB 1490
- anchors
 - aliphatic 1043
- anemia 52
- angiogenesis 36
 - basic principles 34
 - cytotoxic somatostatin analogs 1237
 - imaging 260
 - liver cancer 1551
 - schematic representation 592
 - tumors 13, 65, 591
- angiogenic cascade 34
- angiogenic factors 1419
- angiogenic markers 1443
 - dual targeting 616
 - potential 596
- angiogenic proteins 35
- angiogenin 1453
- angiographic arterial infusion 71
- angiotensin II 75
- angiotensin II-converting enzyme (ACE) 79
- angiotensin-converting proteins 341
- animal studies
 - albumin-based nanoparticles 1139
- anionic phospholipids 1373
- AnnA1 knockout mice 65
- Annexin-A1 (AnnA1) 344
- antagonistic analogs
 - GHRH 1249
- antagonists 1219
 - bombesin/GRP 1219
 - GHRH 1247
- Antennapedia protein
 - *Drosophila* 1189
- anthracycline-based regimen 12
- anthracyclines 929, 933
- anthrax toxin 1450, 1465
- anti-ASase antibodies 631
- anti-CEA monoclonal antibody
 - murine 25
- anti-CEA scFv–Fc variants 99
- anti-HER2 liposomes
 - Fab ϵ fragments 958
- anti-HER2 mAb 957
- anti-MDR agent
 - amlodipine 1026
- anti-mouse antibody
 - human 111
- anti-murine antibody
 - human 455
- anti-PEG Ig-mAb 79
- antiangiogenesis 617
- antiangiogenic agents 599
- antiangiogenic approved therapies 593
- antiapoptotic proteins 1228
- antibiotics 1519
 - benzoquinone ansamycin 605
 - chromophore dienediynes 1543
- antibodies 5
 - ADCs 110
 - ADEPT 19
 - affinity 21, 100
 - anti-ASase 631

- antibodies (*contd.*)
 - anti-PEG Ig-mAb 79
 - antibody–toxin conjugates 14
 - antienzyme 22
 - binding 7
 - BsAbs 430, 483
 - caveolae-dependent trafficking 329
 - chimeric 292, 444
 - clinical trials of ADCs 14
 - conjugated 449
 - delivery agents 423
 - DiBi mini- 459
 - dimeric domain 457
 - effector functions 291, 293
 - empowered 49
 - engineered fragments 424, 425
 - fluorescently labeled 331
 - HAMA 455
 - hetero-oligomeric 455
 - human anti-mouse 111
 - humanized 414, 444
 - indirect photosensitizer-linker-mAb conjugates 1580
 - intact 424, 425
 - loaded 111
 - marketed therapeutic 445
 - monoclonal 24
 - neutralizing 1459
 - nucleosome-specific 961
 - photosensitizer targeting 1575
 - radiolabeled 412
 - radionuclide delivery 411
 - TandAb 469
 - targeting ligands 1381
 - targeting moieties 1205
 - therapeutic agents 443
 - “two-in-one” 453
- antibody fragments
 - PEGylated 634
- antibody-based macromolecular systems 37
- antibody-dependent binding 1203
- antibody-dependent cellular cytotoxicity (ADCC) 38, 432
- antibody-directed enzyme prodrug therapy (ADEPT) 17
- antibody-mediated long-circulating liposome 955
- antibody-modified liposomes 962
- antibody-targeted chemotherapy 94
- antibody-targeted liposomal drugs 968
- antibody-targeted liposomes 954, 956
- antibody–drug conjugates (ADCs) 450
 - auristatin-based 305, 309
 - calicheamicin-based 94, 253
 - cancer therapy 295
 - cytotoxic 72
 - linker technologies 69
 - most successful 86
 - pharmacokinetics 300
- antibody–maytansinoid conjugates (AMCs) 375
 - activation 385
 - clinical trials 384
 - structure 378
- anticancer agents 1013
 - carriers 747
 - complexation 253
 - extravasation 45
 - LDL 763
 - serum albumin 763
 - structure 7
 - transferrin 763
- anticancer combination therapy
 - fixed ratio 1014
- anticancer drugs
 - categories 5
- anticancer formulations
 - liposomal 1007
- anticancer liposomal drugs 954
- anticancer platinum complexes 1605
- antienzyme antibodies 22
- antiestrogens 1612
- antifolates 4
- antigen 1163
 - carcinoembryonic 19, 99, 425, 1167
 - CD19 958
 - hematopoietic 95
 - prostate-specific 562
 - PSMA 295
 - target 295
- antigen presentation
 - FcRn 93
- antigen-binding domain 86, 1447
- antigen-mediated processing 385
 - efficiency 387
- antimetabolites 34
- antineoplastic activity
 - inherent 1195
- antineoplastic agents 275
- antineoplastic cargo 1192
- antineoplastic platinum complexes 853
- antinuclear autoantibodies (AnA) 961
 - nucleosome interaction 964
- antiproliferative effect 952
 - Bac-ELP-p21 688
 - Pen-ELP-H1 686
- antiretroviral therapy
 - HAART 921

- antisense oligonucleotides 543
 - antisense strand phosphorylation 1365
 - antitumor activity
 - paclitaxel and TXP 1340
 - antitumor drugs
 - pH dependence 56
 - antiviral approach 1419
 - APA-AST microcapsules 1088
 - APN 598
 - APN-targeted polymer therapeutics 613
 - apoptosis 43, 1445
 - assays 269
 - CD20 cells 268
 - IAP 1200
 - inhibitor of 1330
 - liver cancer 1551
 - apoptosis-inducing factor (AIF) 1453, 1470
 - apoptotic sensor
 - PhiPhiLux 259
 - APP2 (aminopeptidase P2) 342
 - apparent diffusion coefficient (ADC) 35, 45
 - applications 1263
 - aptamer conjugates 1263
 - biologic 1164
 - CPPs 1190
 - drug delivery systems 1022
 - in vivo 1275
 - PEGylated liposomes 939
 - RNAi 1415
 - SPECT/CT and PET/CT 272
 - theranostic 1180
 - therapeutic 1383
 - approved therapies
 - antiangiogenic 593
 - aptamer conjugates 1263
 - applications 1269
 - toxicology 1276
 - aptamer–chimeric RNA 1274
 - aptamer–DOX conjugates 1270
 - aptamer–siRNA chimeras 1379
 - aptamers 1448
 - isolation 1265
 - secondary structure 1264
 - targeted delivery 1266
 - targeting ligands 1381
 - Ara-C (cytosine arabinoside) 651
 - PEG– 652, 653
 - arabinogalactan–drug conjugates 732
 - arabinoside
 - cytosine 651
 - architectures
 - supramolecular 735
 - area under the time–plasma concentration curve (AUC) 891
 - arming
 - CNTs 1167
 - aromatic amides 1339
 - aromatic systems
 - releasable PEG linkers 646
 - arterial infusion
 - angiographic 71
 - arteriovenous shunt perfusion 37
 - artificial microRNA 1421
 - artificial red blood cells 1062
 - ASGP (asialoglycoprotein) 1524
 - asialoglycoprotein (ASGP)
 - 232, 730, 1524
 - asparagine (ASN) 630
 - aspartate transaminase 1542
 - aspergillins 1453
 - assays 1053
 - apoptosis 269
 - micropanning 16
 - molecular imaging 52
 - assemblies
 - block copolymer 1060
 - astrocytes 1491
 - astrocytomas
 - temozolomide therapy 37
 - athymic nude mice 1229, 1247
 - ATP-binding cassette (ABC) transporters
 - 1493, 1494
 - AUC (area under the time–plasma concentration curve) 891
 - Auger electrons 419
 - emitters 423
 - Aureobasidium pullulans 730
 - aurostatin 258
 - aurostatin E 73, 79
 - trigger group 583
 - aurostatin-based ADCs 305, 309
 - autoantibodies
 - antinuclear 961, 964
 - autophagy 1445
 - Au–Ag nanorods 1272
 - avascular growth phase 34
 - Avastin 473
 - azomethine ylides 1166
- b**
- b emitters 421
 - B lymphocytes 413
 - b-glycerophosphat 1079
 - b-lactamase 828
 - b-lactamase–peptide fusion ligands 5
 - B-lymphoma xenografts 103
 - Bac-ELP-p21 685
 - polypeptides 688

- Bac-ELP1-H1 693
- rhodamine-labeled 695
- Bac-ELP1-p21 689
- backbone degradable polymer carriers 263
- bacterial toxins 1462, 1464
- bacterial vectors 1398, 1401
- bacteriochlorin 1592
- bacteriophages 3
- Bamet-UD2 1613, 1614
- barrier 887
 - biological 887
 - blood–brain 534
 - to cancer development 53
 - endothelial 1140
 - steric 992
- base pairing
 - Watson–Crick 1415
- BBB (blood–brain barrier) 534
- albumin–drug nanoparticles 1138
- alterations in brain tumors 1495
- anatomy 1490
- CNS targeting 1489
- CPPs 1193, 1208
- drug transporters 1492
- BCAs (bifunctional chelating agents) 68
- Bcl-2 1200
- beacon
 - photodynamic molecular 1588
- benign tumors 272
- benzoquinone ansamycin antibiotic 605
- benzyl elimination 559
 - amide/amino-derived linkages 646
 - thiophenol derivatives 567
- β -ligand conjugates
 - releasable 1301
- bevacizumab 1145
- bidirectional transport
 - IgG 91
- Bifidobacterium 1401
- bifunctional chelating agents (BCAs) 68
- bilayer membrane structures
 - closed 990
- bilayers
 - concentric 890
- bilirubin
 - serum 102
- binding 1189
 - antibody-dependent 7, 1203
 - CD30-specific 1470
 - cross-species 111
 - drugs to polymer carriers 250
 - FcRn 95
 - nucleosome 964
 - nucleotide 542
 - specificity 961
- binding pockets
 - hydrophobic 1264
- biocatalytic activation 564
- bioconjugation properties 281
- biodegradability 1163
 - CNTs 1163
 - hydrogels 1072
 - micelles 1113
 - polymers 739, 844
- biodistribution 951
 - analysis 343
 - Fab4D5 108
 - IT-101 736
 - liposomes 970
 - PEG-coated SWNTs 1176
 - pretherapy 434
 - trastuzumab 108
- bioengineering
 - molecular 695
- biologic applications
 - CNTs 1164
- biologic persistence
 - CNTs 1169
- biological barriers 888
- biological half-life
 - targeted toxins 1459
- biology
 - cancer 13
- bioluminescence 35, 51
- biomarker imaging 41
- biomarkers 1359
 - cancer 33
 - common 43
 - hematological 33
 - imaging 34
 - PET/CT 250
 - prognostic potential 273
 - SPECT/CT 258
- biopanning 6
- biopolymers
 - elastin-like 678
- biorecognition 99
 - molecular 268
- biosynthesis
 - eicosanoids 1326
- biotin 1121
 - structure 1304
- biotin–drug conjugate design 1304
- biotin–streptavidin linker 33
- biotinylation 333
- biotransformation
 - CNTs 1177

- biphasic elimination 738
- Bis-AzoPC 1004
- bispecific antibodies (BsAbs) 450, 483
 - clinical trials 464, 465
 - dual action 452, 471
 - radionuclide delivery 430
 - recombinant IgG-like 460
 - single-chain 457
- bispecific molecules
 - recombinant 457
- bispecific targeted toxins 1450
- bispecific T-cell engager (BiTE) 464
- bisphosphate therapy
 - adjuvant 807
- bivalent binding 453
- bivatuzumab mertansine 297
- BL22 1477
- bladder cancers 1219
 - cytotoxic somatostatin analogs 1219
 - urinary 1231
- bleeding tendency 19
- bleomycin 921
- block copolymers 1099
 - amphiphilic 1099
 - assemblies 1060
 - micellar structures 1053
 - MPEG–HPAE 1106
 - PEO/PPO 675
 - self-assembly 1054
- blocking of FcRn-recycling 102
- blood 951
 - activity curves 97
 - composition 748
 - high pressure 75
 - pharmaceutical nanocarriers 952
 - proteins 747
 - vessels 34, 911
- blood cells
 - artificial 1062
- blood flow
 - tumors 37
- blood pH 1100
- blood-borne delivery 43
- blood–brain barrier (BBB) 534
 - albumin–drug nanoparticles 1138
 - anatomy 1490
 - CNS targeting 1489
 - CPPs 1193, 1208
 - drug transporters 1492
- BMC (methyl- β -cyclodextrin) 1141
- BODIPY-ivermectin 1494
- bolus 915
- bombardment
 - particle 1371, 1401
- bombesin-releasing peptide 1244
 - receptors 1244
- bombesin/GRP antagonists 1244
- bonds 1361
 - cis double 1361
 - cleavable 247
 - disulfide 1002
 - hydrazone 258
 - thioether 258, 273
 - unsymmetrical disulfide 1295
- bone marrow 96
- bone marrow-derived myeloid cells 34
- bone metastases
 - SPECT/CT 277
- bone tumors
 - primary 1614
- boron neutron capture therapy (BNCT) 276, 538
- boronated PAMAM dendrimer 538
- bortezomib 908
- bovine serum albumin (BSA) 566, 1123
 - cationic 1138, 1504
- bow-tie dendrimer 526
- BR96–doxorubicin 95
- bradykinin 79
- brain metastases 432
- brain tumors 1489
 - BBB alterations 1489
 - cytotoxic somatostatin analogs 1241
- branched elimination linkers 573
- branched galactose units 714
- branched subunits 278
- branching 275
 - aberrant 693
 - structural motif 514
- breaking point
 - predetermined 555, 874
- breast cancer 929
 - cytotoxic somatostatin analogs 1238
 - LHRH cytotoxic analogs 1229
 - metastatic 930
 - PLD 916, 930
- brentuximab vedotin 259
- BSA (bovine serum albumin) 566, 1123
- BsAbs (bispecific antibodies) 450, 464, 483
 - clinical trials 465
 - dual action 452, 471
 - formats 454
 - radionuclide delivery 430
 - recombinant IgG-like 460
 - single-chain 457
- budding
 - vesicular 329

- building blocks 573
 - NIPAAm 671
- bypass
 - BBB 1509
- bystander effect 1397
 - antigen-mediated processing 388
- c**
- c-Myc inhibitor 684, 687
- C-terminal tail
 - cytoplasmic 1222
- C-type lectins 596
- cachexia 753
- cadherin
 - vascular endothelial 1179
- Caenorhabditis elegans* 1416
- calcium phosphate
 - lipid-coated 1379
- calicheamicin 1283
 - ADCs 93, 248
 - discovery 95
 - prodrug 75
- camelids 463
- camptothecin (CPT) 251, 762, 1305, 1334
 - analogs 641
 - MAG–CPT 852
 - PEG–CPT 855, 856
 - polymer-based combination therapy 809
 - polysaccharide–drug conjugation 713
- CanAg antigen 382
- canalization 35
- cancer 952
 - biology 13
 - biomarkers 33
 - breast 929
 - development barriers 38
 - drug categories 5
 - hormone-dependent 807
 - human experimental 1228
 - limits of conventional chemotherapy 34
 - liver 1520
 - metabolism and proliferation 36
 - neuroendocrine 271
 - NSCLC 27, 851, 1623
 - ovarian 854, 925
 - polymer-based combination therapy 805
 - pre-antibody era 442
 - progression and control 1324
 - prostate 65
 - PUFAs cell lines 1331
 - staging 273
 - thyroid 278
 - zzz 278
- cancer chemotherapy
 - tumor-targeted liposomes 955
- cancer gene therapy
 - vectors 1398
- cancer stem cells (CSCs) 95
- cancer therapeutic agents
 - molecularly targeted 808
- cancer therapy 1163
 - ADCs 295
 - CNT constructs 1168
 - empowered antibodies 46
 - hyperthermia 668
 - poloxamers 676
 - targeted 1263
- cancer-targeting ligands 3, 14
- cancer-targeting ligand–drug conjugates 27
- cancer-targeting peptides 6
 - cell-penetrating 1189
- capan-1 human pancreatic tumor xenograft model 1034
- capillaries
 - cerebral 1491
- caplostatin 822
- carbodiimides 708, 760
- carbohydrate-based spacers 1293
- carbon nanotubes (CNTs) 546, 1163, 1180
 - arming 1167
 - biodegradability 1169
 - biologic applications 1164
 - biotransformation 1177
 - cancer therapy constructs 1168
 - chemistry 1164
 - drug delivery systems 896
 - environmental concerns 1171
 - interactions with cells and tissues 1168
 - MWNT 546, 896, 1165
 - PEGylation 1173
 - pharmacokinetics 1170, 1173
 - properties 1163
 - SWNT 896, 1165
 - toxicity 1170
- carboplatin 829, 860, 1344, 1605
- carboplatin–folate conjugates 1612
- carboxy groups
 - activated 1312
- carboxylic groups
 - immunoglobulins 969
- carboxymethyl-Dex (CM-Dex) 713
- carboxymethyl-pullulan (CM-Pul) 730
- carboxypeptidases 34
 - G2 (CPG2) 4, 20
- carcinoembryonic antigen (CEA) 18, 425, 1167
 - anti-CEA scFv–Fc variants 99

- monoclonal antibodies 24
- carcinogenesis
- siRNA/miRNA 1361
- cardiotoxicity 20, 608, 918
- care
 - supportive 25
- carriers 1099
 - albumin 786
 - anticancer agents 747
 - colloidal 1099
 - hepatotropic 1532
 - macromolecular 684
 - multifunctional polymeric 249
 - nanoparticulate 952
 - nanosized 1523
 - passive 1575
 - polymeric 99, 264, 812, 839, 841
 - reduced folate 1284
 - site-specific 951
 - temperature-sensitive 674
 - thermo-responsive ELP 692
- cascade
 - angiogenic 34
- cascade polymer 540
- catabolism
 - maytansinoids 303
- cathepsin 40, 554
- cathepsin B 876, 877
- catheter
 - PICC 6
- cationic albumin-conjugated PEGylated nanoparticles 1149
- cationic BSA 1138, 1504
- cationic lipids/liposomes 1371
- cationic polymers 1373
- cationized albumin 1501
- caveolae 329
- caveolae-dependent trafficking of antibodies 329
- caveolae-mediated transcellular delivery 1057
- caveolar transport 1134
- caveolin-1 knockout mice 330
- cavities
 - dendritic 256
- CBI (cyclopropabenzindol-4-one) 67
- CBR (clinical benefit rate) 932
- CC531 960
- CD13 613
- CD19 antigen 958
- CD20 cells
 - apoptosis 269
- CD22 102
- CD30-specific binding 1470
- CD33
 - hematopoietic antigen 96
- CD44 598, 724
- CDC (complement-dependent cytotoxicity) 291
- CDDP (cisplatin) 714, 829, 939, 1035, 1605, 1608
- CDK (cyclin-dependent kinase) 1201
- cDNA 1418
- CDP (cyclodextrin-containing polycation) 1375
- CEA (carcinoembryonic antigen) 18, 425
 - anti-CEA scFv–Fc variants 99
 - monoclonal antibodies 24
- CEA (carcinogenic embryonic antigen) 1167
- CED (convection enhanced delivery) 538
- cell adhesion molecule (EpcAM) 464
- cell cycle 11
 - modulation 1198
 - phases 11
- cell delivery 1087
- cell penetration 995
 - triggerable 995
- cell-based SELEX 1265
- cell-binding domain 1447
- cell-penetrating peptides (CPP) 1189
 - applications 1189
 - cancer targeting 1189
 - cell cycle modulation 1198
 - cellular uptake 681
 - delivery vectors 1208
 - internalization routes 1190
 - intracellular delivery 680
 - oncogenic signaling 1198
 - RNA interference 1365
 - sequences 1191
 - targeted toxins 1443, 1456
 - targeting 1202, 1381
 - TAT 1113
- cell-penetrating small molecules 534
- cell-targeting reactivity 993
- cells 1053
 - artificial 1053
 - bone marrow-derived myeloid 34
 - cancer stem 95
 - CD20 269
 - Daudi 470
 - death 1445
 - dividing 17
 - endothelial 66, 332, 591
 - hematopoietic 93
 - hypoxic 267
 - interactions with CNTs 1168
 - Kupffer 1366

- cells (*contd.*)
 - living 1265
 - log/fractional cell kill 14
 - MX-1 1135
 - neoplastic 236
 - neovasculature 595
 - NK 449
 - proteome 336
 - triggered targeting 995
 - tumor-initiating 111
- cellular cytotoxicity
 - antibody-dependent 291
- cellular proliferation 35, 685
- cellular structure
 - MRI 44
- cellular transport 1300
- cellular uptake 1133
 - CPPs 681
 - macromolecules 112
- cell–cell contacts 35
- cell–cell junction
 - endothelial 72
- central nervous system (CNS) 1138
 - liposomal drug delivery 1502
 - polymer nanoparticles 1505
 - targeting 1489
- cerebral capillaries 1491
- cervical tumor hypoxia 41
- CEUS (contrast enhanced ultrasound) 49
- CFPAC-1 tumor xenograft 1348
- chain reaction 1415
 - dendritic 570
 - polymerase 1416
- chain transfer agent (CTA) 266
- chains
 - surface-grafted 992
- chaotic microcirculation
 - tumors 43
- chaotic microvasculature 65
- charged dendrimers 535
- chelate-functionalized SWNTs 1176
- chelating agents
 - bifunctional 92
- chelators 421
- chemical adaptors 573
- chemical conjugation 1271
- chemical cross-linking 1074
- chemical modification strategies 1362
- chemical stability
 - siRNA/miRNA 1365
- chemical vectors 1371
- chemical warfare 3
- chemically incompatible agents 1026
- chemically labile linkers 72
- chemistry 1163
 - and architecture 278
 - CNTs 1164
 - cross-linking 70
 - linkage site 70
 - polysaccharide–drug conjugation 707
- chemoembolization
 - transarterial 1521
- chemotherapeutics 325
 - cytotoxins 3
 - growth factor targeted delivery 1311
 - platinum-based combination 37
 - PUFAs 1323
 - temperature-sensitive carriers 674
- chemotherapy 951
 - calicheamicin ADCs 94
 - combination 806, 1013
 - cytotoxic 4, 121
 - first-line/second-line 13
 - HCC 1522
 - limits 34
 - proliferation imaging 266
 - tumor hypoxia 51
 - tumor-targeted liposomes 955
- CHEMS (cholesteryl hemisuccinate) 998, 1377
- chimeras 1361
 - aptamer–siRNA 1361
 - fiber/knob 1432
- chimeric (mouse/human) mAb 239
- chimeric antibodies 444
- chimeric anti-CD52 antibody 292
- chimeric RNA
 - aptamer– 1274
- chitin 717
- chitosan 1079, 1084, 1374
- chitosan-coated nanoparticles 894
- chitosan–drug conjugates 717
 - N-succinyl-chitosan derivatives 722
- chlorambucil 1336
- cholesterol 889, 1371, 1580
 - conjugation 1275
 - plasma 753
- cholesterol paclitaxel prodrug nanoparticles 1042
- cholesteryl hemisuccinate (CHEMS) 968, 1377
- cholesterylhexadecyl ether (CHE) 1041
- CHOP regime 442
- choroid plexus epithelium 1503
- chromophores 1178
 - chromophore-labeled AN-152 1227
 - dienediyne antibiotic 1543
- chronic hepatitis 1519

- chylomicrons 751
- cilengitide 603
- cintredekin besudotox 1479
- circulating half-life
 - aptamer conjugates 1275
- circulating time
 - liposomes 956
- circulation
 - enterohepatic 1613
- circulation lifetime
 - hydrophobic drugs 1041
- cirrhotic livers 1542
- cis-aconityl linkage 721
- cis-double bonds 1372
- cisplatin (CDDP) 714, 829, 1035
 - discovery 1605
 - mode of action 1608
 - PEGylated liposomal formulations 939
- cisplatin/irinotecan 1021, 1035
- cleavable bond 101
- cleavable conjugates 387
- cleavable linkers 299
 - intracellularly 79
 - on-demand 26
- cleavable prodrugs 951
 - enzymatically 527
 - half-lives 562
- cleavage 951
 - enzymatic 25
 - glycosidase-based 71
 - reductive 26
 - thiol–disulfide exchange 379, 388
- “click chemistry” 263
- clinical applications 951
 - liposomes 951
 - local jet-injection 1407
 - self-immolative linkers 582
 - SPECT/CT and PET/CT 272
- clinical benefit rate (CBR) 932
- clinical development 1219
 - GHRH antagonistic analogs 1219
 - LHRH cytotoxic analogs 1235
 - LipoPlatin 1622, 1623
 - liposome formulations 1006
 - LipOxal 1624
 - liver tumor targeting 1550
 - PDT 1591
 - polymer-based combination therapy 816
 - ProLindac 1625
 - radioimmunoimaging 431
 - RIT 434
 - serum proteins 788
 - targeted toxins 1472
- clinical experience
 - drug–polymer conjugates 839
- clinical oncology 35
- clinical practice
 - imaging techniques 23
- clinical studies 1133
 - albumin-based nanoparticles 1133
 - CombiPlex® formulations 1036
 - CPX-1/CPX-351 1036, 1038
- clinical trials 951
 - ADCs 14
 - ADEPT 16
 - AMCs 384
 - anticancer liposomal drugs 954
 - BsAbs 464, 465
 - drug–polymer conjugates 847, 848
 - effector function-enhanced antibodies 293
 - gene therapy 1402
 - “Gene Therapy Clinical Trials Worldwide” 1431
 - INNO-206 864
 - liver tumors 1550
 - local gene delivery 1395
 - micellar structures 1055
 - PEG prodrugs 855
 - PEG–drug conjugates 653, 654
 - PGA 858
 - phase I 1038
 - phase II 1039
 - *Pseudomonas aeruginosa* exotoxin A 1474
 - recombinant bispecific molecules 464
 - RIP 1475
 - RNAi 1384, 1417
 - siRNA/miRNA 1383
 - targeted diphtheria toxin 1473
 - targeted protein toxins 1476
 - two-phase 26
- clinical tumor imaging 247
- cloaking 536
- clodronate 1616
- clonal selection 49
- closed bilayer membrane structures 990
- Clostridium* 1401
- CLR101 866
- cluster effect 1613
- CM-Chit (carboxymethyl-chitin) 719
- CM-Dex (carboxymethyl-Dex) 713
- CM-Pul (carboxymethyl-pullulan) 730
- CMC (critical micelle concentration) 892
- CMC-544 102, 107
 - clinical development 110
- CMDA 25
- CMV (cytomegalovirus) promoter 1424

- CNS (central nervous system) 1138
 - liposomal drug delivery 1502
 - polymer nanoparticles 1505
 - targeting 1489
- CNTs (carbon nanotubes) 546, 1163
 - arming 1167
 - biodegradability 1169
 - biologic applications 1164
 - biotransformation 1177
 - cancer therapy constructs 1168
 - chemistry 1164
 - drug delivery systems 896
 - environmental concerns 1171
 - interactions with cells and tissues 1168
 - PEGylation 1173
 - pharmacokinetics 1170, 1173
 - properties 1163
 - theranostic applications 1180
 - toxicity 1170
- coated CNTs 1173
- cobalamin 1300
- coding tag 23
- coencapsulation 940
- coformulation
 - in liposomes 1043
- coil conformation
 - random 247
- colbalamin–cochicine conjugates 1302
- colloidal carriers 1099
- colloidal silica particles 333
- COLO205 382, 389, 390
- colon tumor xenograft
 - DLD1 1346
- colorectal cancer 1219
 - cytotoxic somatostatin analogs 1219
 - LHRH cytotoxic analogs 1234
 - xenografts 645
- comb polymer
 - self-immolative 580
- combination therapy 805, 1013
 - administration strategies 1022
 - combination chemotherapy 1020
 - drug ratios 812
 - fixed ratio 1014
 - nab-rapamycin/perifosine 1147
 - physicochemical characterization 816
 - platinum-based 37
 - polymer-based 805
 - preclinical models 815
 - target sites 811
 - targeted protein toxins 1445, 1446
- combinatorial peptide libraries
 - OBOC 3, 12, 13, 16
- CombiPlex® formulations 805
 - hydrophobic agents 1040
 - liposome-based 1029
 - nanoparticle 1040
 - reactive agents 1033
- combotox 1480
- compartmentalization 414
- competition assay 1228
- complement-dependent cytotoxicity (CDC) 291
- complete response (CR) duration 1036
- completeness
 - analytical 337, 338
- complex proteomes 337
- complex self-immolative architectures 573
- complexation
 - anticancer agents 253
- compromised microcirculation 43
- computed tomography (CT) 887
 - contrast agents 42
 - SPECT/CT and PET/CT 247
 - tumor imaging 34, 46
- concentric bilayers 890
- conditional RNA systems 1422
- confocal microscopy
 - xzy 1378
- conjugated antibodies 449
- conjugated pyrrolic ring systems 1571
- conjugates 1519
 - (un-)cleavable 387
 - acid-activated PEG–drug 651
 - acid-sensitive 772, 1536
 - acyl hydrazone-based 1299
 - ADCs 295
 - albumin 772
 - alginate–drug 730
 - AMCs 378
 - antibody–maytansinoid 375
 - antibody–toxin 16
 - aptamer 1263, 1269
 - aptamer–DOX 1270
 - arabinogalactan–drug 732
 - biotin–drug 1304
 - cancer-targeting ligand–drug 27
 - carboplatin–folate 1612
 - chitosan–drug 717
 - clinical experience 839
 - colbalamin–cochicine 1302
 - combination therapy 810
 - cyclodextrin–drug 735
 - DCM–Dex–Gal4A–CDDP 718
 - Dex-based drug 711
 - Dex-peptide–MTX 719
 - disulfide-linked trastuzumab 383

- drug–albumin 789
- drug–polymer 275, 1529
- enzyme-cleavable photosensitizer 1586
- FA–fluorescein 1300
- Fleximer–camptothecin 845
- folic acid–drug 27
- gadolinium–dendrimer 540
- growth factor–drug 1283, 1579, 1581
- HA–drug 724
- heparin–drug 727
- hydrolyzable drug–PEG 844
- LHRH 1223
- ligand–drug 3
- mAb–maytansine 85
- mAb–photosensitizer 1577
- natural polymer–drug 730
- nonantibody proteins 1580
- paclitaxel–PGA 840
- pectin–drug 732
- PEG–drug 627
- PEG–lipid 955
- PEG–phospholipid 1001
- PEG–TSCA 610
- peptide hormone–drug 105
- peptide ligand–drug 101
- pH-sensitive 731
- polygalactosamine–drug 735
- polymer peptide–drug 150
- polymer-based combination therapy 818
- polymer–drug 34, 93, 707, 830
- polymer–photosensitizer 1584, 1586
- polypeptide–drug 671
- polysaccharide-based 747
- protein–photosensitizer 1583
- PUFA–drug 1359
- PUFA–taxoid 1346
- pullulan–drug 729
- releasable β -ligand 1301
- releasable dual-drug 1295
- RGD-based polymer–drug 601
- second-generation taxoid 1332, 1345
- selectin-targeted polymer–drug 612
- small-molecule–photosensitizer 1588, 1589
- stable 1287
- synthetic approaches 759
- TAT–polymeric micelles 1114
- transferrin 772
- trastuzumab–maytansinoid 384
- vitamin–drug 1283
- water-soluble 272, 1298
- xyloglucan–drug 734
- conjugation 1263
- bioconjugation properties 281
- chemical/physical 1271
- cholesterol 1275
- covalent 248
- doxorubicin (DOX) 75
- DOX–CPP 1193
- drug 1125
- lysine and cysteine residues 92, 93
- polysaccharide–drug 707
- PUFAs/cytotoxic drugs 1332
- SC-PEG 632
- SS-PEG 630
- strategies 376
- streptonigrin 66
- technologies 297
- Consortium for Resourcing and Evaluating
AMS Microdosing (CREAM) 36
- contrast agents 276
- CT 47
- MRI 1063
- contrast enhanced ultrasound (CEUS) 49
- control
- cancer 1324
- controlled drug delivery 1099
- convection enhanced delivery (CED) 538
- conventional anticancer agents
- structure 7
- conventional chemotherapy 1071
- limits 34
- side-effects 16
- conventional drugs
- ELP-delivery 689
- conventional hybridoma production 414
- convergent synthesis
- dendrimers 516
- copolymers 1071
- acrylic 1071
- amphiphilic block 1103
- block 675, 1053
- block assemblies 1060
- fluorescently labeled HPMA 247
- long-circulating 272
- triblock 1061
- core
- multifunctional 278
- core/membrane lipid-based nanoparticles 1376
- coregistration 1361
- anatomic information 282
- image 257
- core–shell structure 1058
- corona (shell) 1103
- cotyledones 90
- coupling
- transmural 42, 46

- covalent conjugation 248
 - DOX–CPP 1193
- covalent modification
 - CNTs 1166, 1178
- CPG2 (carboxypeptidase G2) 20
 - inactivation 7
- CPP (cell-penetrating peptides) 1189
 - applications 1189
 - cancer targeting 1189
 - cell cycle modulation 1198
 - cellular uptake 681
 - delivery vectors 1208
 - internalization routes 1190
 - intracellular delivery 680
 - oncogenic signaling 1198
 - RNA interference 1365
 - sequences 1191
 - targeted toxins 1443, 1456
 - targeting ligands 1381
 - tumor targeting 1202
- CPT (camptothecin) 528, 641, 762, 1305, 1334
 - MAG–CPT 852
 - PEG–CPT 855, 856
 - polymer-based combination therapy 809
- CPX-1 1032
 - clinical studies 1038
 - efficacy 1034
 - phase I clinical trials 1038
 - phase II clinical trials 1039
 - preclinical pharmacology 1033
- CPX-351 1013
 - clinical studies 1036
 - preclinical pharmacology 1030
- CPX-351 liposomes 1030
- CPX-571 1033
 - efficacy 1036
 - preclinical pharmacology 1035
- cracking pattern 582
- CREKA peptide 1149
- Cremophor micelles 1592
- Cremophor-paclitaxel 1141, 1153
- Cre–loxP system 1423
- critical micelle concentration (CMC) 892
- critical solution temperature 668, 672
- cross-linked albumin matrix 1136
- cross-linked knedel
 - shell 892
- cross-linked micelles
 - virus-mimetic 1122
- cross-linked polymer network 1071
- cross-linkers 887
 - diacid-derivatized 887
 - self-immolative 556
 - sulfhydryl-reactive 1137
 - thiophilic heterobifunctional 1289
- cross-linking 85
 - glutaraldehyde 1137, 1145
- cross-reactive determinants 961
- cross-species binding 111
- crystallizable
 - fragment 85
- CSCs (cancer stem cells) 95
- CT (computed tomography) 805
 - contrast agents 42
 - SPECT/CT and PET/CT 247, 805
 - tumor imaging 34, 46
- CTA (chain transfer agent) 250
- culture
 - endothelial cells 332
- cutaneous contaminations 276
- cutaneous T-cell lymphoma (CTCL) 1472
- CVX-241 471
- cyclic oligosaccharides 735
- cyclic RGD-based vehicles 608
- cyclin-dependent kinase (CDK) 1201
- cyclization
 - strategies 556
- cyclodextrin 867
- cyclodextrin-containing polycation (CDP) 1375
- cyclodextrin–drug conjugates 735
- cyclophosphamide 938
- cyclopropabenzindol-4-one (CBI) 66
- cyclosporine 1210
- cylindrical micelles 1054
- cynomolgus monkeys 99
- Cys34 777
 - in situ binding 779
- cysteine 1001
 - dicysteine- β -cyclodextrin 735
 - SPARC 1135, 1155, 1323
 - thiol–disulfide exchange cleavage 388
- cysteine residues
 - conjugation 92, 93
- cytarabine 1030
- cytochrome P450 enzyme 1349
- cytokines 3
 - pro-inflammatory 894
- cytomegalovirus (CMV) promoter 1424
- cytoplasmic C-terminal tail 1222
- cytoplasmic signaling region 88
- cytosine arabinoside (Ara-C) 651
 - PEG– 652, 653
- cytosolic drug release 1121
- cytosolic pH 53
- cytotoxic ADCs
 - linkers 72

- cytotoxic analogs
 - LHRH 1221
- cytotoxic bombesin analogs 1245
- cytotoxic chemotherapy 3, 21
- cytotoxic drugs 11
 - molecular weight 1287
 - PUFA synergy 1331
- cytotoxic peptide analogs
 - targeted 1220
- cytotoxic somatostatin analogs 1219
 - structure 1219, 1239
 - targeted 1236
- cytotoxic T-lymphocyte (CTL) 451
- cytotoxicity 951
 - 2C5-modified liposomes 965
 - antibody-dependent cellular 291
 - complement-dependent 291
 - dendrimer-related 536
 - dendritic architecture 535
 - doxorubicin/vincristine 1029
- cytotoxins
 - chemotherapeutic 3
- d**
 - D-amino acid oxidase (DAO) 822
 - structure 824
 - D-amino acids 1224
 - DAC (Drug Affinity Complex) 103
 - DAPK2 1471
 - DAR (drug-to-antibody ratio) 72
 - database “Gene Therapy Clinical Trials Worldwide” 1431
 - Daudi cells 470
 - Daudi lymphoma disease 1454
 - daunorubicin 1030
 - DAVLBH 1293
 - DC-SPION (dendrimer-coated superparamagnetic iron oxide nanoparticles) 266
 - DCM-Dex-Gal4A-CDDP conjugate 718
 - deblocking 564
 - decay products
 - radioactive 420
 - decoding
 - phage-display libraries 6
 - degradation domain
 - oxygen-dependent 1205
 - deleterious drug–drug interactions 1033
 - delivery 1026, 1495
 - agents 423
 - aptamer isolation 1265
 - aptamers 1266
 - blood-borne 43
 - caveolae-mediated transcellular 1057
 - cell 1087
 - controlled 1099
 - convection enhanced 538
 - conventional drugs 689
 - CPP vectors 1208
 - delivery platforms 1263
 - EPR effect heterogeneity 72
 - extracellular 1365
 - gene 542, 1085
 - growth factor targeted 1311
 - HCC treatment 1522, 1530
 - hepatotropic systems 1528
 - heterogeneous 1008
 - hormone-mediated nuclear 261
 - hydrophobic small-molecule drugs 1139
 - in vivo studies 390
 - interstitial barriers 46, 47
 - intracavitary 422
 - intracellular 680
 - intranasal 1509
 - ligand-based systems 1189
 - lipid-like molecules 1373
 - liposomal 1502, 1616
 - local gene 1391
 - magnetically controlled 1507
 - micellar structures 1053
 - multiagent drug vehicles 1022
 - nanoparticle 1271
 - nanoscale systems 887, 1013
 - nucleic acids 1195
 - oligonucleotides 1150, 1195
 - oral 721
 - pathophysiological characteristics 65
 - peptide receptors 1220
 - peptide-mediated 610
 - peptides 682
 - pH-triggered micelles 1099
 - photosensitizer 1571
 - polymeric systems 1619
 - proteins 1150, 1151
 - radionuclide delivery vector 1207
 - radionuclides 411
 - respective 1446, 1607
 - RNA approaches 1361, 1368
 - serum proteins 752
 - site-specific 1054
 - small-molecule 1270
 - tailor-made hydrogels 1071
 - targeted drug 1284
 - toxins 1455
 - uniformity 989
 - vascular characteristics 65
 - vehicles 1573
 - DENA (diethylnitrosamine) 1538

- dendrimer phthalocyanine-encapsulated polymeric micelle (DPc/m) 537
- dendrimer-coated superparamagnetic iron oxide nanoparticles (DC-SPION) 266
- dendrimer-related cytotoxicity 536
- dendrimers 1489
 - boronated PAMAM 538
 - bow-tie 526
 - brain targeting 1508
 - charged 535
 - cytotoxicity 535
 - diagnostic application 539
 - divergent/convergent synthesis 516
 - end-group functionality 248
 - functional groups 270
 - gene delivery 542
 - glycopeptide 24
 - intracellular trafficking 535
 - MTX-loaded 534
 - nanoglobular platform 609
 - pharmacokinetics 535
 - polyplexes 1374
 - self-immolative 575, 577
 - targeting moiety 251
 - therapeutic application 545
 - translocation 535
 - water-soluble 579
- dendritic architectures
 - complexation of anticancer agent 254
- dendritic cavities
 - doxorubicin (DOX) 255
- dendritic chain reaction 570
- dendritic compound
 - YEE(GalNAcAH)₃ 1525
- dendritic end-groups
 - cloaking/masking 536
- dendritic polyglycerol 527
- dendritic polyglycerolamine 543
- dendritic polymers 1443
 - drug conjugation 1443
 - drug encapsulation 1121
 - oncology 274
 - targeting modalities 530
- dendritic scaffold
 - drug–polymer conjugates 275
- dendritic structures
 - drug-conjugated 271
- denileukin diftitox 1472
- depolymerization 577
- depression of the immune system 18
- derivatization
 - PEGylated liposomes 955
- deshielding 1115
 - pH-dependent 1203
- design 1283
 - biotin–drug conjugates 1283
 - drug-encapsulated nanoparticles 1527
 - drug-free macromolecular therapeutics 273
 - LHRH cytotoxic analogs 1223
 - PET 275
 - polymer–drug conjugates 97
 - targeted protein toxins 1443
- desolvation
 - ethanol 1145
- detection of recurrence 274
- development
 - drugs 51
- Dex-based drug conjugates 711
- Dex–MMC 712
- Dex-peptide-MTX conjugate 719
- dexamethasone 917, 933
- dextran (Dex) 711
- DHA (docosahexaenoic acid) 1324
- DHA–10-hydroxycamptothecin 1334
- DHA–EPA–propofol 1335
- DHA–illudin M 1336
- DHA–LNA–DOX 1334
- DHA–methotrexate 1338
- DHA–paclitaxel (TXP) 1338
 - antitumor activity 1340
 - pharmacokinetics 1339
- DHA–SB-T-1214 1347
- DHAD 1547, 1553, 1554
- diabodies 887
 - diabody chains 456
 - PSCA-specific 430
 - single-chain 105
- diacid-derivatized cross-linker 893
- diacyl lipids 1580
- diagnostics 1605
 - dendrimers 539
 - modern 14
- diammineplatinum(II) fragment 1609
- DiBi mini-antibodies 459
- 1,5-dichloro-3-thiapentane 4
- dicysteine- β -cyclodextrin 735
- dienediyne antibiotic
 - chromophore 1543
- diethylenetriaminepentaacetic acid (DTPA) 270, 1303
- diethylnitrosamine (DENA) 1538
- diferric transferrin 749
- differential accumulation/internalization 1263
- differential regulation of gene expression 47
- differentiation
 - benign/malignant tumors 272

- diffuse large B-cell lymphoma (DLBCL) 110
- diffusion 33
- diffusion coefficient
 - apparent 38, 54
- diffusion-weighted imaging (DWI) 46
- dimeric domain antibodies 457
- dimethylformamide 1166
- diode
 - light-emitting 693
- 1,2-dioleoyl-sn-glycero-3-
 - phosphoethanolamine (DOPE) 998, 1371
- dipalmitoylphosphatidylcholine (DPPC) 1574
- dipalmitoylphosphatidylglycerol (DPPG) 1617
- diphtheria A chain 1310
- diphtheria toxin 1083, 1448
 - targeted 1473
- direct mAb–photosensitizer conjugates 1578, 1579
- directional placental transport 90
- disease control 1039
- disialoganglioside GD2 958
- diskoidal porous silicon microparticles 899
- disorder band 1165
- disorganized microcirculation 43
- dispersed SWNTs 1172
- dispersions
 - phospholipid 889
- distearoylphosphatidylcholine (DSPC) 908
- distribution
 - ADME 1173, 1175
- disulfide bonds 989
 - reduction 989
 - unsymmetrical 1295
- disulfide bridge 457
- disulfide formation 24
- disulfide linkers 78
 - trastuzumab conjugates 383
- disulfide-based linkers 376, 1288
- divergent synthesis
 - dendrimers 516
- DLBCL (diffuse large B-cell lymphoma) 111
- DLD1 human colon tumor xenograft
 - P-gp+ 1346
- DLT (dose-limiting toxicity) 991, 1032
- DM1 376
- DNA 1605
 - adduct formation 1605
 - inhibition of synthesis 235
 - LPD 1376
 - plasmid 1367, 1407
 - platinum complexes 1609
 - RACE 1418
 - recombinant 27
- DNA adducts
 - platinum– 1035
- DNA alkylator 1336
- DNA intercalators 806
- DNA-damaging agent 94
- DNA/polymer complexes 1085
- DNM 732
- docetaxel 3, 675, 1345
 - polysorbate-based 1141, 1154
- docetaxel-loaded micelles 675, 677
- dock-and-lock system 431
- docosahexaenoic acid (DHA) 1324
- dodecapeptides 4
- domains 1443
 - functional 1443
 - organization 443
 - targeted protein toxins 1447
- DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) 998, 1371
- dose
 - maximum tolerated 1013, 1032, 1037
- dose-dependent efflux 389
- dose-escalation study 25
- dose-finding
 - CNTs 1171
- dose-limiting toxicity (DLT) 991, 1032
- dosing
 - PLD 912
- dosing platform
 - ratiometric 1040
- double bonds
 - cis 1372
- double-prodrug concept 556
- DOX-DEX 817, 820
- DOXO-EMCH 780, 784
 - hepatotropic delivery 1536
 - pharmacokinetics 790
- DOXO-HYD 777
- doxorubicin (DOX) 299
 - aptamer–DOX conjugates 1270
 - conjugation 75
 - covalent conjugation with CPP 1193
 - dendritic cavities 255
 - Dex–DOX conjugates 713
 - DHA–LNA–DOX 1334
 - encapsulated 914
 - fluorescent properties 608
 - hydrazone-bound DOX moiety 613
 - hydrogel-based therapy 1081
 - hypoxic regions 45
 - LHRH cytotoxic analogs 1224
 - L-HSA–DOX 1536, 1540

- doxorubicin (DOX) (*contd.*)
 - ligand-assisted vascular targeting 605
 - liposomes 809
 - micelle formulation 676
 - molecular structure 1270
 - nanogels 1125
 - nanoparticles 809
 - PEG-liposomes 953
 - PEGylated liposomal 909
 - perivascular distribution 17
 - pH-sensitive pullulan–DOX conjugate 731
 - pH-triggered drug release 1112
 - pharmacokinetics 790
 - polyglycerol–DOX prodrugs 536
 - polysaccharide–drug conjugation 711
 - 2-pyrrolino-DOX 1225, 1246
 - self-immolation 562
 - toxicity profile 915
 - transdrug 1546, 1553
 - transferrin conjugates 772
 - VAD 918, 933
- doxorubicin/vincristine 1029
- doxorubicin–HSA nanoparticles 1147
- DPc/m (dendrimer
 - phthalocyanine-encapsulated polymeric micelle) 537
- DPPC (dipalmitoylphosphatidylcholine) 1574
- DPPG (dipalmitoylphosphatidylglycerol) 1617
- Drosophila
 - antennapedia protein 1189
- Drug Affinity Complex (DAC) 103
- drug and linker selection 93
- drug approval 53
- drug carriers 989
- macromolecules 100
- multifunctional polymeric 249
- drug complexes
 - synthetic approaches 759
- drug conjugates 627
 - acid-sensitive 1536
 - albumin 772
 - conjugation strategies 298
 - dendritic structures 271, 1123
 - Dex-based 711
 - growth factor– 1308
 - polysaccharide-based 747
 - polyunsaturated fatty acids (PUFAs) 1359
 - synthetic approaches 759
 - transferrin 772
 - vitamin– 1283
- drug delivery 1489
 - brain targeting 1489
 - controlled 1099
 - EPR effect heterogeneity 72
 - HCC treatment 1522, 1530
 - hepatotropic systems 1528
 - interstitial barriers 46, 47
 - liposomal 1502, 1616
 - macromolecular systems 36
 - magnetic nanoparticles 47
 - magnetically controlled 1507
 - molecularly targeted 238
 - multiagent vehicles 1022
 - nanoparticle-based 346
 - pathophysiological characteristics 65
 - RNA approaches 1361
 - serum proteins 752
 - site-specific 1054
 - strategy 599
 - targeted 1284
 - vascular characteristics 65
 - vehicles 1573
- drug delivery systems 1013
 - applications 1013
 - dual- 1026
 - ligand-based 1189
 - micellar structures 1053
 - MSV 896
 - nano- and microparticulate 887
- drug design 1013
 - FcRn 85
 - IgG 85
 - PET 275
 - serum albumin 85
- drug development
 - imaging techniques 21
- drug encapsulation 1133
 - dendritic polymers 1133
 - nab technologies 1137
 - nanoparticles 1527
- drug entrapment
 - supramolecular 520
- drug nanoparticles
 - synthetic approaches 759
- drug ratios 1014
 - combination therapy 812
- drug release 1099
 - cytosolic 1099
 - kinetics 814
 - pH-triggered 1104
 - self-immolative dendrimers 577
 - two-step mechanism 555
- drug-free macromolecular therapeutics 267
 - design 273
- drug-loaded liposomes 28, 954
- drug-to-antibody ratio (DAR) 72

- drugs 989
 - actual delivery 989
 - albumin–drug nanoparticles 1133
 - amphipathic 909
 - antibody-targeted liposomal 968
 - anticancer liposomal 954
 - bacterial toxins 1462, 1464
 - BBB transporters 1492
 - categories 5
 - circulation lifetime 1041
 - cytotoxic 15
 - development and validation 51
 - EPR effect 68
 - export pumps 1493
 - externally activated release 1001
 - human proteins 1468
 - hydrophilic 1081
 - hydrophobic 719, 909
 - LDL–drug complexes 786, 792
 - lipophilic 761
 - liposomal 890
 - modification with CPPs 1191
 - peptides 1082
 - pH dependence 56
 - plant toxins 1464, 1466
 - polymer carrier binding 250
 - and prodrugs 20
 - protein-based 103, 1082
 - release from polymersomes 1061
 - respective delivery concept 1446, 1607
 - RNAi 1384
 - safety 257
 - site-specific attachment 91
 - small-molecule 1079
 - solubility 840
 - solubilizers 867
 - targeting 951, 1489
 - vector-coupled 1499
- drug–albumin conjugates
 - clinical development 789
- drug–drug interactions 1015, 1349
 - deleterious 1033
- drug–polymer conjugates 839
 - clinical experience 839
 - clinical trials 847, 848
 - dendritic scaffold 275
 - derivatives 861
 - hepatotropic delivery 1529
 - HPMA 842
 - second generation 865
 - stable 871
- drug delivery vehicles
 - PDT 1576
- DSPC (distearoylphosphatidylcholine) 908
- DTPA (diethylenetriaminepentaacetic acid) 270, 1303
- DTX 4
- DTX-encapsulated nanoparticle–aptamer (DTX-NP-Apt) 1271
- dual action BsAbs 452, 471
- dual formulation 1023
- dual targeting
 - angiogenic markers 616
- dual-acting prodrugs 784, 878
 - structure 787
- dual-color screening method 20
- dual-drug conjugates
 - releasable 1295
- dual-drug delivery systems
 - dual systems 1026
- dual-phase release mechanism 844
- dual-targeted microbubbles 38
- dual-variable-domain immunoglobulins (DVD-Igs) 461
- dividing cells 17
- DWI (diffusion-weighted imaging) 46
- DX-8951 862
- dye
 - Nile Red 581
- dynamic g-scintigraphy 85, 343
- dynamics
 - lipid acyl tail 999
- e**
- E-selectin-mediated endocytosis 959
- E1B-55K protein 1432
- EC145 1289, 1290, 1293
- ECF (extracellular fluid) 19
- ECM (extracellular matrix) 724
 - integrin ligands 603
 - integrins 596
- economic analysis 936
- ectopic RNA 1368
- Edman chemistry 20
- effector function-enhanced antibodies 293
- efficiency 951
 - CPP cellular uptake 681
 - polymer carriers 104
- efflux effect
 - P-glycoprotein 965
- EGF (epidermal growth factor)
 - CNTs 1167
- EGFR (epidermal growth factor receptor) 533, 1313
 - immunoliposomes 958
 - liposomes 940
- EGF–polylysine- β -amanitin 1311

- eicosanoids
 - biosynthesis 1326
- eicosapentaenoic acid (EPA) 1324
- elastin-like biopolymers 678
- elastin-like polypeptide (ELP) 678
 - intracellular delivery 680
 - purification 680
 - synthesis 678
- electrons
 - Auger 419, 423
- electrophoretic techniques 748
- electroporation 1370
- electropores 1405
- electrostatic repulsion 996
- elimination 1013
 - benzyl 646
 - biphasic 738
 - paclitaxel prodrugs 1042
 - plasma 1043
 - strategies 558
 - thiophenol derivatives 567
- elimination linkers 1071
 - branched 573
 - multiple 575
- elimination-based trigger groups 564
- elongated spacers 257
- embolic microbeads 1080
- embolization 1089
- embryonic antigen
 - carcinogenic 1167
- emerging delivery platforms 1263
- empowered antibodies
 - cancer therapy 44
- encapsulated doxorubicin 914
- encapsulation 1163
 - CNTs 1163
 - drug 1122
 - liposomal 1616
- ϕ -end chemical phosphorylation 1365
- end-groups
 - dendritic 248, 536
- endocrine approaches 1221
- endocrine therapy 807
- endocytic pH-triggered drug release 1106, 1115
- endocytic vesicles 991
- endocytosis 107
 - E-selectin-mediated 959
 - folate receptor-mediated 1284
 - receptor-independent 1122
 - receptor-mediated 1115, 1269
- endogenous silencing pathway
 - saturation 1368
- endohedral filling 1165
- endometrial cancer 1230, 1240
- endonucleases
 - fungal 1453
- endopeptidase
 - thermostable human 23
- endosomal escape 247
- endosomal pH 1059
- endosomal release 1367
- endosomes 296, 1100
- endothelial barrier 1140
- endothelial cadherin
 - vascular 1179
- endothelial cell membranes
 - luminal 334
- endothelial cell-targeted polymer therapeutics 597
- endothelial cells 1189
 - activation 591
 - in culture 332
 - neovasculature 595
 - proliferating 592
 - proteins 66
 - proteome 336
- endothelial cell–cell junction 72
- endothelial expression 618
- endothelial growth factor
 - vascular 34, 261, 539, 637, 1198, 1330, 1416
- endothelial sprouting 34
- endothelium 1189
 - fenestrated 328
 - sinusoidal 328
 - vascular 327
- enediyne aglycone functionality 95
- energy-independent membrane translocation 1189
- engineered antibody fragments 424, 425
- engineering 1189
 - IgG 95, 96
 - IgG half-life 101
- enhanced mutagenesis 51
- enhanced permeability and retention (EPR) 259, 326
 - CPPs 1194, 1203
 - drug–polymer conjugates 877
 - heterogeneity 72
 - PEG–drug conjugates 639
 - pharmaceutical nanocarriers 952
 - polymer-based combination therapy 810
 - tumor targeting 85
- enterohepatic circulation 1613
- envelope-type nanodevice
 - multifunctional 1377
- environmental concerns
 - CNTs 1171

- enzymatic activation 564
- enzymatic cleavage 25
- enzymatically cleavable peptide linker 784
- enzymatically cleavable prodrugs 527
 - half-lives 562
- enzyme prodrug systems 29
- enzyme-cleavable photosensitizer conjugates 1586
- enzyme-labile linkers 79
- enzyme-related targeted protein toxins
 - human 1469
- enzymes 1359
 - ADEPT 20
 - cytochrome P450 1349
 - ERK1/2 1329
 - GDEPT 1397
 - innate 1000
 - PDEPT/PELT 812
 - tumor-associated 250
 - tumor-specific 1056
- EORTC (European Organization for Research and Treatment of Cancer) 937
- eosin-stained femurs 1032
- EPA (eicosapentaenoic acid) 1324
- EpCAM (cell adhesion molecule) 464
- epidemiology of HCC 1519
- epidermal growth factor (EGF)
 - CNTs 1167
- epidermal growth factor receptor (EGFR) 533, 1313
 - immunoliposomes 958
 - liposomes 940
- epidermal necrolysis 297
- epigenetic mechanisms 592
- epigenetic suppression 1423
- epirubicin 24, 824
- epithelial cell adhesion molecule (EpCAM) 960
- epithelium
 - choroid plexus 1503
- EPR (enhanced permeability and retention) 259, 326
 - CPPs 1194, 1203
 - drug–polymer conjugates 877
 - heterogeneity 72
 - PEG–drug conjugates 639
 - pharmaceutical nanocarriers 952
 - polymer-based combination therapy 810
 - tumor targeting 85
- ErbB2 1206
- Erbitux 453
- ERK1/2 (extracellular signal-regulated kinase) 1329
- erythrocytes 52
- erythrodysesthesia
 - palmar–plantar 915, 916, 934
- ester linkage 608, 638
- esters
 - spontaneous ring-closure 557
- estradiol 829
- estrogen receptor 807
- estrogens 1612
- ethanol desolvation 1145
- European Organization for Research and Treatment of Cancer (EORTC) 937
- Evans blue 66, 70, 756
- Evans blue–albumin 73
- excretion
 - ADME 1173, 1178
- exopolysaccharide 730
- experimental cancers
 - human 1228
- exponential enrichment
 - SELEX 1264, 1265
- export proteins
 - ABC 1497
- Exportin-5 1435
- expression
 - endothelial 618
- externally activated drug release 1001
- externally activated targeting 1001
- extracellular acidity
 - tumors 1100
- extracellular delivery
 - siRNA/miRNA 1365
- extracellular fluid (ECF) 19
- extracellular matrix (ECM) 724
 - integrin ligands 603
 - integrins 596
- extracellular pH-triggered drug release 1104
- extracellular signal-regulated kinase 1/2 (ERK1/2) 1329
- extravasation 23, 33
 - anticancer agents 45
 - Evans blue–albumin 73
 - nanocarriers 991
 - tissue 535
- EZN-2208 642, 655, 866, 868
 - preparation 643
- f**
- Fab (fragment of antigen binding) 86
- Fab4D5
 - biodistribution 108
- Fab ϕ fragments 272
 - anti-HER2 liposomes 958
- FAMTM-siRNA 1379
- fatigue 19

- fatty acid binding protein (FABP)
 - 1325, 1326
- fatty acids 1219
 - ω -amino 1219
 - polyunsaturated 1359
- FA–fluorescein conjugate 1300
- Fc fusion technology 95
- Fc receptor
 - neonatal 85
- FcRn–ligand interactions 89
- FcRn-mediated recycling 92
 - blocking 102
- FcRn-mediated transport 93
- FcRn (neonatal Fc receptor) 85
 - altered binding 95
 - antigen presentation 93
 - discovery 87
 - kidneys 94
 - liver 95
 - structure 88, 89
- FDA approval 53
- 18F-FDG 250
 - radioimmunotherapy 266
- FDG (fluorodeoxyglucose) 1102
- Fe-transferrin 754
- femurs
 - eosin-stained 1032
- fenestrated endothelium 328
- Ferumoxtran-10 229
- fetal neonatal immune thrombocytopenia (FNIT) 91
- fetuin 1532
- 18F-FLT 250, 257, 266
- FGF 533, 727
- fiber/knob chimeras 1432
- fibroblast growth factor 533, 727
- fibroblasts
 - stromal 46
- filling
 - endohedral 1165
- first-generation PEG linker 630
- first-line chemotherapy 13
- FITC (fluorescein isothiocyanate) 110
- fixed ratio anticancer combination therapy 1014
- flavoprotein
 - mitochondrial 1470
- flexibodies 460
- tetraivalent 458
- Fleximer–camptothecin conjugate 845
- flip-flop process 1325, 1326
- flippase 1422
- floxuridine/irinotecan 1032
- fluid 1099
 - extracellular 19
 - intracellular 41
- fluid pressure
 - interstitial 36, 37, 39, 40, 41
- fluid-phase pinocytosis 1114
- fluorescein 249
 - FA–fluorescein conjugate 1300
- fluorescein isothiocyanate (FITC) 110, 965
 - -labeled proteins 757
- fluorescence 35, 49
- fluorescence resonance energy transfer (FRET) 247
- fluorescent liposomes 1003
- fluorescent nab-paclitaxel 1140
- fluorescent probes
 - tumor detection 541
- fluorescent properties
 - DOX 608
- fluorescent protein 1189
 - GFP 262, 1198, 1421
- fluorescently labeled antibodies 331
- fluorescently labeled HPMA copolymers 107
- fluorinated pyrimidine 1032
- 5-fluoro-2'-deoxyuridine 1534
- 5-fluorocytosine 1406
- fluorodeoxyglucose (FDG) 1102
- fluorogenic monomer units 580
- fluorophore-labeled AN-152 1227
- fluorophores 1178
- 5-fluorouracil (5-FU) 806
 - toxicity profile 915
- fluorouridine (FURD) 1147
- FMISO 268
- FNIT (fetal neonatal immune thrombocytopenia) 91
- focused ultrasound
 - high-intensity 669, 670
- focused ultrasound treatment 1499
- folate conjugates
 - carboplatin– 1612
- folate receptor 235
- folate receptor-mediated endocytosis 1284
 - preclinical pharmacology 1289
- folate receptor-targeted liposomes 1001
- folate receptor-targeted micelles 1119
- folate-conjugated micelles 1057
- folate-modified liposomes 967
- folding
 - head-to-tail 459
- FOLFIRI regimen 1038, 1039
- FOLFOX regimen 1039
- folic acid 1283
 - dendrimers 259

- heparin–folic acid–PTX 729
- structure 1284
- folic acid–drug conjugates 27
- formaldehyde 558
- formulations
 - liposome-based 1013
- four-arm PEG 645
- FR-targeted immunotherapy 1298
- fractional cell kill 14
- fragment crystallizable 85
- fragment of antigen binding (Fab) 86
- freeze-drying
 - liposomes 970
- FRET (fluorescence resonance energy transfer) 249
- frustrated phagocytosis 1172
- 5-FU (5-fluorouracil) 806
- functional domains 1446
- functional groups
 - dendrimers 270
- functional imaging 249
- functional lymphatics 37
- functionality
 - end-group 248
- functionalized lipids 996
- functionalized nanotubes 1168
- fungal endonucleases 1453
- FURD (fluorouridine) 1147
- fusion
 - vesicular 329
- fusion ligands
 - b-lactamase–peptide 5
- fusion proteins 1443
 - nonglycosylated 23
 - recombinant 1457
- fusion technology 1519
 - Fc 95
 - serum albumin 102, 104
- Fv
 - single-chain 452, 459

g

- g emitters 417
- g-scintigraphy 952
 - dynamic 85, 343
 - planar 85
- gadolinium–dendrimer conjugates 540
- galactosamine 1529, 1551
- galactose units
 - branched 714
- gangliosides 910
- gastric cancers
 - cytotoxic somatostatin analogs 1243
 - gastrin-releasing peptide (GRP) 1244
 - antagonists 1245
 - receptors 1244
 - gastroduodenal artery 1559
 - gastrointestinal distress 19
 - gastrointestinal toxicities 1037
 - GCIG (Gynecologic Cancer Intergroup) 929
 - GD2 958
 - gel-phase membranes 992
 - gelation
 - in situ 1077
 - geldanamycin 605
 - Gelonium multiflorum 1270
 - gel–solid transition region 998
 - gels
 - hydro- 1072
 - gemcitabine 1043
 - gemtuzumab ozogamicin 75, 275
 - calicheamicin ADCs 95
 - GEM–DOX 824
 - structure 827
 - gene correction therapy 1392
 - gene delivery 1058
 - dendrimers 542
 - hydrogel-based therapy 1084
 - intratumoral 1404
 - local 1391
 - locoregional 1405
 - technologies 1404
 - gene expression 1328
 - differential regulation 47
 - long-term 1399
 - gene suppression 1397
 - gene therapeutic strategies 1391
 - gene therapy 1391
 - clinical trials 1392
 - nanoparticles 237
 - vectors 1398
 - “Gene Therapy Clinical Trials Worldwide” database 1431
 - gene transfer 1399
 - gene vectors 346
 - gene-directed enzyme prodrug therapy (GDEPT) 1397
 - general toxicity 1461
 - genetic heterogeneity
 - tumors 65
 - genome-wide libraries 1429
 - genomic instability 51
 - genomics approaches
 - tissue-specific targets 335
 - GFP (Green Fluorescent Protein) 262, 1198, 1421
 - plasmids encoding 995

- GHRH (growth hormone-releasing hormone) 1220
 - antagonistic analogs 1249
 - antagonists 1247
 - structure 1248
 - Gliadel wafers 1479
 - glioblastoma multiforme 1490, 1496
 - gliosis 40
 - GLP toxicology studies 1038
 - glucocorticoids 1559
 - glucopyranose 711
 - glucosamine 727
 - glucose analog tracer 1102
 - glucose oxidase (GOD) 1085
 - glucose pathway 38
 - glucosylation 534
 - glutaraldehyde 760
 - cross-linking 1137, 1145
 - glutathione 86, 1504
 - glycopeptide dendrimers 24
 - glycopeptide library 20
 - glycoprotein
 - α 1-acid 1341
 - glycosidase-based cleavage 71
 - glycoside clusters
 - synthetic 1525
 - glycosylation pattern 292
 - GM-CSF (granulocyte macrophage colony-stimulating factor) 1083
 - GOD (glucose oxidase) 1085
 - Golgi apparatus 775
 - Good Manufacturing Practice (GMP) 1174
 - standards 27
 - gp60 receptor 792, 1134
 - gp60-mediated transcytosis 1324
 - GPCR superfamily 1244
 - gradient
 - manganese sulfate 1028
 - granulocyte macrophage colony-stimulating factor (GM-CSF) 1083
 - granuloma formation 1171
 - granzyme B 1453, 1468
 - Green Fluorescent Protein (GFP) 262, 1198
 - plasmids encoding 995
 - viral vectors 1421
 - groove
 - peptide-binding 88
 - growth
 - repetitive 275
 - growth curve
 - tumors 15
 - growth factor 1219
 - fibroblast 533, 727
 - insulin-like 1249
 - vascular endothelial 34, 261, 539, 637, 1198, 1330, 1416
 - growth factor conjugates 1579, 1581
 - growth factor receptor
 - epidermal 533, 940, 958, 1313
 - growth factor targeted delivery
 - delivery of chemotherapeutics 1311
 - growth factor–drug conjugates 1283
 - growth hormone-releasing hormone (GHRH) 1220
 - antagonistic analogs 1249
 - antagonists 1247
 - structure 1248
 - growth phase
 - pre-/avascular 34
 - GRP (gastrin-releasing peptide) 1244
 - antagonists 1245
 - receptors 1244
 - gutless adenovectors 1431
 - Gynecologic Cancer Intergroup (GCIG) 929
- ## h
- H2-clearance technique 39
 - H460 human tumor xenograft 1349
 - HA (hyaluronic acid) 707
 - HA22 1462, 1477
 - HA22-LR 1463
 - HAART (highly active antiretroviral therapy) 921
 - hair loss 20, 915
 - hairpin RNA
 - short 1392, 1406, 1415, 1418, 1425
 - half-life 1443
 - biological 1443
 - cytotoxic drugs 15
 - enzymatically cleavable prodrugs 562
 - IgG 101
 - serum albumin 107
 - HAMA (human anti-murine antibody) 111, 455
 - hand/foot syndrome 860
 - HA–drug conjugates 724
 - HC homodimerization 461
 - HCC (hepatocellular carcinoma) 871, 1243
 - chemotherapy/targeted therapy 1522
 - epidemiology and incidence 1519
 - multinodular 873, 1557
 - HDAC (histone deacetylase) 27
 - head-to-tail folding 459
 - heat activation 1001
 - heat map
 - synergy 1021
 - heat-sensitive liposomal formulation 1554

- heating system
 - ultrasound-based 669
- hematological biomarkers 33
- hematological malignancies 924
- hematopoietic antigen CD33 95
- hematopoietic cells 93
- hematopoietic progenitor cells 209
- hematoxylin 1032
- heparan sulfate proteoglycan (HSPG) 1503
- heparin–drug conjugates 727
- heparin–folic acid–PTX 729
- hepatic cancers
 - LHRH cytotoxic analogs 1233
- hepatic clearance 629
- hepatic micrometastases 1534
- hepatitis
 - chronic 1519
- hepatobiliary clearance 1178
- hepatocellular carcinoma (HCC) 871, 1243
 - chemotherapy/targeted therapy 1522
 - epidemiology and incidence 1519
 - multinodular 873, 1557
- hepatocytes 1524
- hepatoma 71
- hepatotoxicity 21
- hepatotropic drug delivery systems
 - preclinical development 1528
- HepDirect™ prodrugs 1527, 1529
- HER2-mediated processing 388
- HER2-positive tumors 428
- Herceptin 29, 239, 310, 444, 453, 473
- herpes simplex virus-thymidine kinase (HSV-tk) 1397, 1402
- hetero-oligomeric BsAbs 455
- heterobifunctional cross-linker
 - thiophilic 1289
- heterobifunctional reagents 72
- heterodimerization 462
- heterogeneity 989
 - EPR effect 72
 - genetic 65
- 4D heterogeneity 42
- heterogeneous delivery 1008
- heterogeneous microcirculation 33
- HFT nanoparticles
 - self-assembled 729
- HIF (hypoxia-inducible factor) 65, 1416
- high blood pressure 75
- high-intensity focused ultrasound (HIFU) 669, 670
- highly active antiretroviral therapy (HAART) 921
- highly ordered nanoarchitectures 1054
- hind-leg paralysis 1341
- Hippel
 - von Hippel-Lindau protein 65
- histamine-succinyl-glycine (HSG) 431
- histidine moieties
 - protonation 1125
- histidine-derived polymers 1105
- histocompatibility complex
 - MHC 88
- histone deacetylase (HDAC) 27
- historic approaches 1189
 - conventional chemotherapy 3
 - targeted therapy 26
 - vascular mapping 333
- HIV treatment 1430
- HIV-1 1189
- HPMA–paclitaxel 852
- 13-HODE 1329
- homing peptides 1203, 1207
- homodimerization
 - HC 461
- hormonal approaches 1221
- hormonally responsive tumors 26
- hormone 1219
 - growth hormone-releasing 1219, 1247
 - luteinizing hormone-releasing 533, 1220
- hormone receptor
 - steroid 262
- hormone-dependent cancers 807
- hormone–drug conjugates
 - peptide 150
- hormone-mediated nuclear delivery 261
- hormone-releasing hormone
 - luteinizing 533
- HPAE (poly(β -amino esters)) 1106
- HPMA (N-(2-hydroxypropyl)methacrylamide) 66, 108, 110
 - chemical structure 600
 - DOX-DEX 817, 820
 - drug–polymer conjugates 842
 - fluorescently labeled copolymers 247
 - hydrogel-based therapy 1081
 - ligand-assisted vascular targeting 599
 - liver tumor targeting 1551
 - long-circulating copolymer 270
 - multiblock polyHPMAs 267
 - polymer-based combination therapy 814
 - prodrugs 851
 - trigger group 574
- HSA (human serum albumin) 750, 1133, 1323
 - doxorubicin–HSA nanoparticles 1147
 - MTX conjugates 773
 - MTX–HSA 862
 - structure 86

- HSAB concept 1608
- HSG (histamine-succinyl-glycine) 431
- HSPG (heparan sulfate proteoglycan) 1503
- HSV-tk (herpes simplex virus-thymidine kinase) 1397, 1402
- 5-HT3 inhibitors 20
- human anti-mouse antibody (HAMA) 111
- human anti-murine antibody (HAMA) 455
- human blood
 - composition 748
- human colon tumor xenograft
 - DLD1 1346
- human endopeptidase
 - thermostable 23
- human enzyme-related targeted protein toxins 1469
- human experimental cancers 1228
- human ovarian tumor xenograft
 - A121 1348
- human pancreatic tumor 1034
- human proteins
 - targeted toxins 1468
- human serum albumin (HSA) 750, 1133, 1323
 - doxorubicin–HSA nanoparticles 1147
 - MTX conjugates 773
 - MTX–HSA 862
 - structure 86
- human serum proteome 747
- human telomerase reverse transcriptase (hTERT) 1591
- human tumor xenografts
 - pH 1101
- humanized antibodies 414, 444
- hyaluronic acid (HA) 707
- hyaluronic acid (HA) binding receptor 598
- hybrid imaging modalities 248
- hybrid MRI/PET scanner 248
- hybrid PET/CT 249
- hybrid SPECT/CT 252
- hybridoma production
 - conventional 414
- hybridoma technology 26
- hydrazone bonds 258
- hydrazone linker 1112
 - AcBut 86
 - acid-labile 86, 267
- hydrazone-bound DOX moiety 613
- hydrodynamic injection 1369
- hydrodynamic radius 629
- hydrogel networks
 - polymer 1073
- hydrogel-based therapy 1071
- hydrogels 1071
 - biodegradability 1071
 - formation 1074
 - gene delivery 1085
 - injectable formulations 1076
 - PDT 1087
 - radiotherapy 1088
 - siRNA 1085
 - small-molecule drugs 1079
 - tailor-made 1071
- hydrolysis 558
 - polymers 840
 - unspecific 571
- hydrolyzable drug–PEG conjugates 844
- hydrophilic drugs
 - hydrogel-based therapy 1081
- hydrophilic linkers 74
- hydrophilic molecular tails 1574
- hydrophilicity/hydrophobicity balance 1116
- hydrophobic agents
 - CombiPlex® formulations 1040
- hydrophobic binding pockets 1264
- hydrophobic drugs 719, 909
 - circulation lifetime 1041
- hydrophobic polyglycerol–paclitaxel complex 522
- hydrophobic side-chains 272
- hydrophobic small-molecule drugs
 - delivery 1139
- 10-hydroxycamptothecin 1334
- hydroxyl groups
 - polysaccharides 711
- hyperosmotic solutions 1499
- hypersensitivity reactions 1152
- hyperstabilizing microtubules 895
- hyperthermia 1088
 - cancer therapy 668
 - thermo-responsive polymers 670
- hypoalbuminemia 752
- hypomethylation 1016
- hypothalamic LHRH1 1221
- hypoxia 49
 - cervical tumor 42
 - chemotherapy 49
 - imaging 41
 - molecular imaging 258
 - treatment resistance 49
- hypoxia-inducible factor (HIF) 65, 1416
- hypoxia-selective radiotracers 267
- hypoxic cell fraction 267

i

- IAP (inhibitor of apoptosis protein) 1200
- identification
 - tissue-specific targets 334
- IFN (interferon) 632, 761, 1303, 1403, 1422
- IFP (interstitial fluid pressure) 42, 43, 46
- Ig-mAb
 - anti-PEG 79
- IGF (insulin-like growth factor) 1249
- IgG 1359
 - bidirectional transport 91
 - domain organization 443
 - engineered variants 95, 96
 - Fc fusion technology 95
 - intravenous 102
 - pharmacokinetics 85
 - zzz 85
- IgG Fc
 - structure 86
- IgG-like BsAbs 460
- iliac vessels 4
- illudin M 1336
- image coregistration 257
- imaging 1053
 - adrenocortical tumors 279
 - amino acid transport 257
 - biomarkers 33, 41
 - clinical practice 24
 - diffusion-weighted 46
 - drug development 24
 - functional 249
 - hybrid modalities 248
 - hypoxia 36
 - hypoxic cell fraction 267
 - lymphangiography 25
 - microautoradiography 759
 - microPET 428, 429
 - molecular 42, 249, 258, 270
 - MRI 34, 44, 50, 248, 1062
 - near-IR 38
 - neoangiogenesis 260
 - noninvasive molecular 253
 - optical 35
 - photoacoustic 1180
 - preclinical 258
 - preclinical and clinical 247
 - prognostic potential of biomarkers 273
 - proliferative activity 264
 - protein biosynthesis 257
 - radionuclides 415
 - radiopharmaceuticals 251, 259
 - receptor expression 269
 - targeted agents 233
 - tracers 251, 259
 - tumor 17
 - ultrasound 34, 49
- imaging assays
 - molecular 52
- imaging modalities 1178
- imaging-guided surgery 1062
- imatinib 38
- imidazole-containing polymers 1119
- imidazolidinones 557
- immolation
 - self- 591
- immune stimulation 1367
- immune system
 - depression 18
- immune therapy targeting 68
- immune thrombocytopenia
 - FNIT 91
- immune-privileged sites 94
- immunoconjugates 151
 - radioactive 68
- immunodeficiency disorder
 - severe combined 1429
- immunogene therapy 1394
- immunogenicity 970, 1082
 - targeted toxins 1460
- immunoglobulin receptor
 - polymeric 91
- immunoglobulins 951
 - carboxylic groups 951
 - dual-variable-domain 461
 - naked 449
 - pharmacokinetics 85
 - zzz 85
- immunohistochemistry 1479
- immunohistochemistry-based
 - microenvironment signature 1155
- immunoliposomes 940, 951
- immunologic responses 1169
- immunoPET 418, 431
- immunoproteins
 - small 424
- immunosuppressed status 472
- immunotherapy
 - FR-targeted 1298
- immunotoxins 16, 649, 1444
 - targeting moieties 1448
- in situ albumin technology 784
- in situ binding
 - prodrugs 779
- in situ gelation 1077
- in situ molecular biology 1064
- in situ radiolabeling 333
- in vitro selection
 - tumor cell-targeting phages 3

- in vitro studies
 - albumin-based nanoparticles 1139
- in vivo applications
 - aptamer conjugates 1275
- in vivo selection
 - tumor cell-targeting phages 14
- in vivo studies
 - thermo-responsive ELP carriers 692
- in vivo tissue targeting
 - lungs 341
- inactivation
 - CPG2 4
- incidence of HCC 1519, 1520
- incompatible agents
 - chemically 1026
- indirect photosensitizer-linker-mAb conjugates 1580
- indolequinone 6
- infertility 25
- inflammatory tissues 72
- infusion 1489
 - angiographic arterial 71
 - hyperosmotic solutions 1499
- infusion reactions 918
- inherent antineoplastic activity 1195
- inhibition 1489
 - ABC export proteins 1489
 - DNA synthesis 235
 - P-glycoprotein 1498
- inhibitor of apoptosis protein (IAP) 1200, 1330
- inhibitors 805
 - 5-HT3 20
 - c-Myc 684, 687
 - topoisomerase I 67, 817
- inhibitory response 774
- injectable formulations
 - hydrogel-based 1076
- injection
 - hydrodynamic 1369
- innate enzymes 1000
 - INNO-206 789, 791, 863, 864
 - clinical trials 864
- inorganic nanoparticles 1272
- inotuzumab ozogamicin 251
- insoluble CNTs 1171
- insulin-like growth factor (IGF) 1249
- intact antibodies 424, 425
- integrins 235, 596, 604
 - $\alpha v \beta 3$ integrin 1150
 - ECM ligands 603
 - radiolabeled antagonists 262
- intercalators
 - DNA 806
- interfacial defects
 - pH-triggered 998
- interfacial poly(L-histidine) 1121
- interference
 - RNA 1197, 1415, 1417
- interferon (IFN) 632, 761, 1303, 1403, 1422
- interleukins 761
 - IL-12 1083
 - IL-2 1477
- interlipidic particle formation 1005
- internal pH 53
- internalization 1263
 - differential 1263
 - nontarget 1208
 - photochemical 1589, 1590
 - routes 1190
- interpenetrating polymer network (IPN) 1081
- interstitial barriers
 - drug delivery 46, 47
- interstitial compartment 33
- interstitial fluid pressure (IFP) 41, 43, 46
- interstitial/vascular interface 1102
- interstitium
 - tumor 41, 994
- intestinal peptide
 - vasoactive 968
- intra-arterial therapy 1558
- SMANCS/Lipiodol 1558
- intracavitary delivery 422
- intracellular acidic compartments 92
- intracellular delivery 680
- intracellular fluid 42
- intracellular release
 - FA–drug conjugates 1286
- intracellular trafficking 887
 - dendritic architecture 535
 - MSVs 900
- intracellularly cleavable linkers 78
- intranasal delivery 1509
- intrathecal/intraventricular injection 1498
- intratumoral gene delivery 1404
- intravenous immunoglobulin G (IVIG) 102
- intravenously injected agents 328
- intravital microscopy (IVM) 340
- intussusception 34, 36
- inverse thermal cycling 680
- inverted terminal repeats (ITR) 1433
- ionizable lipids 1372
- IR LED applicator 694
- IR-activated release 1003
- iRGD peptide 1057
- irinotecan 809, 1032

irinotecan/cisplatin 1035
 – synergy heat map 1021
 iron oxide
 – superparamagnetic 56
 irreversible systems 1422
 isolation 1263
 – aptamers 1263
 – maytansinoid metabolites 385
 isothiocyanate
 – fluorescein 757, 965
 isozymes 1349
 IT-101 738
 – biodistribution 736
 ITR (inverted terminal repeats) 1433
 IVIG (intravenous immunoglobulin G) 102
 IVM (intravital microscopy) 340

j

J774.1 macrophages 714
 Jablonski diagram 1570
 jet-injection 1405
 – clinical applications 1407
 junction
 – endothelial cell–cell 72
 juxtamembrane 1309
 JV-1-38 1250

k

K-ras shRNAs 1433
 Kaplan–Meier survival curve 1118, 1501, 1615
 Kaposi's sarcoma 919, 922
 KB cells 1293
 keratinocytes
 – skin 297
 kidneys
 – FcRn 94
 kinase
 – targeted 1471
 kinetics of drug release 814
 knedel
 – shell cross-linked 892
 knob chimeras
 – fiber/- 1432
 “knob-into-hole” mutations 457
 knockout mice 1361
 – AnnA1 65
 – caveolin-1 330
 Kupffer cells 1366

l

L-HSA 1534
 – synthesis 1533
 L-HSA–DOX 1536, 1540

LA/LNA–second-generation taxoids 1349
 labile linkers
 – chemically 72
 lactosaminated albumin 1532
 lactose residues 1540
 ladder synthesis method 21
 LC mispairing 461
 LCP (lipid-coated calcium phosphate) 1379
 LCST (lower critical solution temperature) 668
 – PNIPAAm 672
 LDL (low-density lipoprotein) 747, 1580
 – anticancer agents 763
 – LDL–drug complexes 786, 792
 – radiolabeled 757
 – receptor-mediated uptake 751
 – synthetic approaches 759
 – tumor cells 754
 leakage
 – vascular 66
 lectins
 – C-type 596
 LED (light-emitting diode) 693
 left ventricular ejection fraction (LVEF) 918, 1236
 lentiviral vectors 1392, 1430
 LET (linear energy transfer) 418
 leukemia
 – acute lymphoblastic 3
 leukemic blasts 96
 Lewis lung tumors 913
 LHRH (luteinizing hormone-releasing hormone) 533, 1220
 – conjugates 1223
 – cytotoxic analogs 1221
 – radioiodinated 1225
 libraries 1415
 – genome-wide 1415
 – glycopeptide 20
 – phage-display 3, 335, 1313
 library design
 – OBOC 18
 lifetime
 – circulation 1041
 ligand optimization 22
 ligand-assisted vascular targeting 591
 ligand-based drug delivery systems 1189
 ligand-based nanocarriers 1524
 ligand-targeted approach 531
 ligands 1605
 – ammonia 1605
 – b-lactamase–peptide fusion 5
 – cancer-targeting 3, 14
 – ECM 603

ligands (*contd.*)

- FcRn–ligand interactions 89
- nonantibody 967
- peptidomimetic 23
- SELEX 1264, 1265
- small-molecular-weight 1382
- targeting 1366, 1381
- ursodeoxycholate 1614

ligand–drug conjugates 3

- cancer-targeting 27

ligation

- Staudinger 571

light-emitting diode (LED) 693

Lindau

- von Hippel-Lindau protein 65

linear energy transfer (LET) 418

linkage 1099

- acid-cleavable 1099
- acid-sensitive 5, 738
- amide/amino-derived 646
- cis-aconityl 721
- ester 638
- hydrazone 1112
- succinate 722

linkage site chemistry 69

linker technologies 66

linkers 24

- AcBut hydrazone 86
- acid-labile hydrazone 107, 250
- acid-sensitive 25
- biotin–streptavidin 34
- branched elimination 573
- chemically labile 72
- chemistry 271
- cleavable 299
- cytotoxic ADCs 72
- disulfide 78
- disulfide-based 376, 1288
- enzymatically cleavable 784
- enzyme-labile 79
- ester 608
- first-generation PEG 630
- hydrophilic 74
- intracellularly cleavable 79
- macromolecular 1578
- multiple elimination 575
- noncleavable 71
- noncleavable thioether 272
- nondegradable 602
- on-demand cleavable 26
- optimal 381
- PEG-aldehyde 632
- peptidic 79
- peptidyl 717

- pH-responsive systems 1298

- photosensitizer-linker-mAb conjugates 1580

- releasable PEG 646

- second-generation PEG 631

- selection 95

- self-immolative 553, 1288

- tailor-made 793

- U-PEG-Lys-NHS 635

lipid acyl tail dynamics 999

lipid-based systems 887

lipid-coated calcium phosphate (LCP) 1379

lipidoids 1373

lipids 989

- functionalized 989

- ionizable 1372

- PEG-derivatized 1372

- self-assembled 990

- solid nanoparticles 1508

- tri-/diacyl 1580

Lipiodol 77, 871, 873, 1545, 1555

lipophilic drugs 761

lipophilicity

- small molecules 1287

LipoPlatin 1617

- clinical development 1622, 1623

lipoplexes 1371

- nonviral vectors 1401

- schematic formation 1372

lipopolyplexes 1376

lipoproteins 751

- low-density 747, 754, 1580

liposomal doxorubicin

- PEGylated 909

liposomal drug delivery 1502

liposomal drug delivery

- platinum complexes 1616

liposomal drugs 890

- anticancer 954

- preparation and administration 968

liposomal encapsulation 1616

liposomal formulations 1007

- heat-sensitive 1554

liposomal siRNA 900

liposome targeting

- nonantibody ligands 967

liposome-based formulations 889

- CombiPlex® 1029

- CPX-351 1013

liposome-membrane-incorporated synthetic polymers 966

liposomes 888

- 2C5-modified 965

- aggregation 1005

- anti-HER2 958
- antibody-mediated long-circulating 955
- antibody-modified 962
- antibody-targeted 956
- behavior affecting factors 908
- cationic 1371
- circulating time 956
- clinical applications 953
- coformulation in 1043
- CPX-351 1030
- DOX 809
- drug delivery vehicles 1573
- drug-loaded 29
- dual-drug delivery systems 1026
- fluorescent 1003
- folate receptor-targeted 1001
- folate-modified 967
- formation 907
- freeze-drying 970
- immuno- 951
- non-PEGylated 907
- nonviral vectors 1401
- nucleosome-specific antibodies 961
- PEGylated 891, 952
- PEGylated CPP- 1205
- PELT 812
- protein-coupled 1504
- responsive 989
- sterically stabilized 909, 913
- structure 907, 908
- targeted 955, 1502
- targeting 3
- liposome–polycation–DNA (LPD) 1376
- LipOxal
 - clinical development 1624
- liver 95
 - X/myc transgenic 1548
- liver resection 1521
- liver toxicity 102
- liver tumors 1519
 - clinical developments 1519
 - nanoparticles 1546
 - reticuloendothelial system 1527
 - targeting 1519
- living cells 1265
- LLP2A
 - peptidomimetic ligand 24
- LNA–DOX
 - DHA- 1334
- loaded antibodies 111
- loading
 - noncovalent 248
- loading capacity 815
- local ablative therapy 1521
- local gene delivery 1391
 - clinical applications 1407
 - clinical trials 1395
 - physical methods 1404
 - technologies 1404
- localization 1569
 - SLN 276
 - specific 420
 - subcellular 683, 1573
- localization signal
 - nuclear 423
- locked nucleic acid (LNA) 1364
- locoregional gene delivery 1405
- log cell kill 14
- logP value 1079
- long-circulating copolymer 270
 - HPMA 270
- long-circulating liposomes
 - antibody-mediated 955
- long-circulating polymer carriers 264
- long-term gene expression 1399
- longevity
 - pharmaceutical nanocarriers 952
- low-density lipoprotein (LDL) 747, 1580
 - radiolabeled 757
 - receptor-mediated uptake 751
 - synthetic approaches 759
 - tumor cells 754
- lower critical solution temperature (LCST) 668
 - PNIPAAm 672
- LPD (liposome–polycation–DNA) 1376
- luciferase 1503
- luminal endothelial cell membranes 334
- lung cancer
 - non-small-cell 27, 851, 1623
- lung targeting 341, 343
- lung tumors
 - Lewis 913
- luteinizing hormone-releasing hormone (LHRH) 533, 1220
 - conjugates 1223
 - cytotoxic analogs 1221
 - radiiodinated 1225
- LVEF (left ventricular ejection fraction) 918, 1236
- lymph nodes 14
- lymphangiogenesis 37
- lymphangiography 22
- lymphatic drainage 591
- lymphatic vessels 17

- lymphatics
 - functional 46
 - lymphoblastic leukemia
 - acute 3
 - lymphocytes
 - B 413
 - lymphoma
 - non-Hodgkin's 38, 103, 294, 449, 1233, 1243
 - lymphotropic nanoparticles 227
 - MRI 229
 - LyP-1 1195, 1208
 - lysine amino groups 1578
 - lysine modification 86
 - lysine residues
 - conjugation 92, 93
 - lysines
 - alkylating 298
 - lysis 292
 - redirected 451
 - lysomotropic effect 270
 - lysosomal activation 387
 - lysosomal membrane 250
 - lysosomes 296, 1100
- m**
- M-components
 - urine 934
 - mAb 176
 - mAb–maytansine conjugates 85
 - mAb–photosensitizer conjugates 1577
 - indirect 1580
 - macromolecular carrier 684
 - macromolecular drug delivery systems 35
 - macromolecular drugs
 - EPR effect 68
 - macromolecular linkers 1578
 - macromolecular photosensitizers 1585
 - macromolecular prodrugs 271, 782
 - serum 755
 - macromolecular therapeutics
 - drug-free 267
 - macromolecules 1361
 - drug carriers 99
 - polysaccharides 701
 - structural factors 101
 - macrophages 546
 - J774.1 714
 - splenic 1366
 - macropinocytosis 1060
 - MAG (methacryloyl-glycine) 852
 - magnetic field-activated release 1006
 - magnetic nanoparticles 44
 - magnetic resonance imaging (MRI) 34, 44
 - cellular structure 46
 - hybrid MRI/PET scanner 248
 - lymphotropic nanoparticles 229
 - magnetic nanoparticles 47
 - metabolic response 46
 - theranostic micelles 1062
 - magnetically controlled CNS delivery 1507
 - magnetofection 237
 - major histocompatibility complex (MHC) 88
 - MALDI-TOF 22
 - maleimide group 784
 - maleimide-carrying phospholipids 969
 - maligancies
 - hematological 924
 - malignant diseases 14
 - malignant melanomas 1219
 - cytotoxic somatostatin analogs 1219
 - LHRH cytotoxic analogs 1233
 - malignant tumors 1443
 - differentiation 272
 - microvasculature 38
 - mammalian toxins 1480
 - manganese sulfate gradient 1028
 - manufacturing
 - GMP 1174
 - MAPG (melanoma-associated proteoglycan NG2) 460, 468
 - mapping 1189
 - accessible vascular targets 430
 - historic approaches 333
 - proteome 336
 - validation 339
 - markers 1189
 - angiogenic 596, 616
 - tumor-labeling 1192
 - marketed therapeutic antibodies 445
 - masking
 - dendritic end-groups 536
 - mass spectrometry (MS) 1053
 - data quantification and normalization 338
 - proteome mapping 336
 - matrix 1053
 - extracellular 596, 724
 - remodeling 35
 - matrix metalloprotease (MMP) 554, 1056
 - CPPs 1204
 - matrix remodeling 35
 - MT1 959
 - PDT 1588
 - maurocalcine 1194
 - maximum tolerated dose (MTD) 1013
 - CombiPlex® formulations 1032
 - CPX-351 1037

- maytansine
 - structure 376
- maytansinoids 99, 310
 - accumulation of metabolites 391
 - AMCs 375
 - catabolism 303
 - isolation of metabolites 385
 - trastuzumab conjugates 384
- MB07133 1531
- MDA435/LCC6 tumors 1028
- MDR (multidrug resistance) 34, 1026
 - conventional chemotherapy 16
 - CPPs 1194
 - multifunctional pH-sensitive micelles 1117
 - PUFAs 1345
- MDR-1 protein 1221
- MDX-447 464
- measles virus 1404
- medical sciences
 - nanotechnology 887
- medicinal mushrooms 19
- medicine
 - personalized 793
- melamine polymers 536
- melanoma-associated proteoglycan NG2 (MAPG) 460, 468
- melanomas
 - malignant 1233, 1243
- membrane transfer domain 1447
- membrane type-1 matrix metalloproteinase (MT1-MMP) 959
- membranes 1189
 - endothelial cell 334
 - energy-independent translocation 1189
 - fusion 1005
 - gel-phase 992
 - lipopolyplexes 1376
 - lysosomal 252
 - PUFA–drug conjugates 1325
 - rigidity 993
- MEND (multifunctional envelope-type nanodevice) 1377
 - structure 1378
- mesochlorin 821
- metabolic response
 - MRI 46
- metabolism 1163
 - ADME 1163, 1177
 - cancer 36
 - tumors 65
- metalloprotease
 - matrix 35, 554, 1056, 1204, 1588
- metastases 952
 - bone 277
 - brain 432
 - pretherapeutic detection 275
 - spontaneous 35
- metastatic breast cancer 930
- metastatic micronodule 74
- methacryloyl-glycine (MAG) 852
- methide
 - quinone 559
- methotrexate (MTX) 4, 259
 - clinical development 789
 - DHA– 1338
 - HSA conjugates 773
 - MTX-loaded dendrimers 534
 - MTX–HSA 862
 - serum proteins 762
- methoxy poly(ethylene glycol) (mPEG-OH) 628
- methyl PEG (MPEG) 1106
- methyl- β -cyclodextrin (BMC) 1141
- MFECF 27
- MHC (major histocompatibility complex) 88
- mi interfering RNA (miRNA) 1361, 1421
 - therapeutic applications 1383
- mice 1219
 - athymic nude 1219, 1247
 - knockout 66, 330
 - nu/nu 1297
 - SCID 105, 472, 1348
- micellar nanodevices
 - multifunctional 1064
- micellar structures 1053
 - drug delivery systems 1053
 - self-assembled 611
- micelle-based polymer systems 892
- micelles 1099
 - biodegradable 1099
 - CMC 892
 - Cremophor 1592
 - cylindrical 1054
 - docetaxel-loaded 675, 677
 - DOX 676
 - DPc/m 537
 - drug delivery vehicles 1573
 - dual-drug delivery systems 1027
 - folate receptor-targeted 1119
 - folate-conjugated 1057
 - hydrophilicity/hydrophobicity balance 1116
 - multifunctional pH-sensitive 1114
 - pH-sensitive polymeric 1054
 - pH-triggered 1099, 1113
 - polyion complex 1058

- micelles (*contd.*)
 - polymeric 1508
 - smart polymeric 1054
 - SMA–pirarubicin 75
 - stable 673
 - surface charge 1113
 - TAT-functionalized 1121
 - theranostic 1062
 - unimolecular 258
 - virus-mimetic cross-linked 1122
- Michael-type addition 559
- retro-aldol–retro-Michael tandem reaction 566
- microautoradiography 759
- microbeads
 - embolic 1080
- microbubbles 34, 49
 - dual-targeted 38
- microcapsules 581
 - APA-AST 1088
 - self-immolative polymers 581
- microcirculation 1133
 - chaotic 44
 - disorganized 44
 - heterogeneous 33
- microdosing 36
- microenvironment 1133
 - immunohistochemistry-based signature 1133
 - pathophysiological 48
 - tumor 251
- microflow rate 41
- micrometastases
 - hepatic 1534
- Micromonospora echinospora 95
- micronodule
 - metastatic 74
- micropanning assay 14
- microparticles
 - diskoidal porous silicon 899
- microparticulate drug delivery systems 887
- microPET imaging 428, 429
- microPET/CT 254
- microprojectiles 1371
- microscopic tumors 33
- microscopy 1163
 - intravital 340
 - xzy confocal 1378
- microsequencing 19, 21
- microspheres
 - albumin 761
- microtubule-stabilizing agents (MTSA) 24
- microtubules 247
 - hyperstabilizing 895
 - staining 272
- microvascular networks 1003
- microvasculature 1361
 - chaotic 65
 - normal tissues and malignant tumors 38
- microvessels 1361
 - formation 34, 36
 - functional irregularities 38
 - structural irregularities 38
 - tumor 331
- mimetic peptide
 - p21 685
- mimicry
 - vascular 34, 36
- mini-antibodies
 - DiBi 459
- minibodies 424
- minimal residual disease (MRD) 466
- miRNA (mi interfering RNA) 1361, 1421
 - therapeutic applications 1383
- mispairing
 - LC 461
- mitochondrial flavoprotein 1470
- mitochondrial targeting 260, 273
- mitomycin 676
- mitomycin C 722, 932
 - PUFA–mitomycin C 1336
- mitoxantrone-loaded nanoparticles 1547, 1553
- MM-111 469
- MMAE (monomethyl auristatin E) 73, 79
 - trigger group 583
- MMC 722
- MMP (matrix metalloprotease) 554, 1056
 - CPPs 1204
 - matrix remodeling 35
 - MMP-2 1464
 - MT1 959
 - PDT 1588
- modern diagnostics 14
- modification 1163
 - covalent 1163, 1178
 - CPP drugs 1191
 - noncovalent 1167
- 2C5-modified liposomes 965
 - cytotoxicity 965
- modulation
 - micelle surface functionality 1113
- modulators
 - vascular 79
- moieties
 - targeting 258

- molecular adapter
 - multifunctional 1466
- molecular beacon
 - photodynamic 1588
- molecular bioengineering 695
- molecular biology
 - in situ 1064
- molecular biorecognition 268
- molecular imaging 249
 - assays 52
 - hypoxia 258
 - noninvasive 253
 - probes 43
 - SSTR 270
- molecular structure
 - repetitive growth 513
- molecular weight 1283
 - cytotoxic drugs 1283
 - polymer carriers 108
- molecularly targeted agents 808
- molecularly targeted drug delivery 238
- molecules 1361
 - cell-penetrating small 534
 - lipidoids 1373
 - recombinant bispecific 457
 - tandem 468
- monoaqua complex 1607
- monoclonal antibodies (mAb) 239
 - anti-HER2 mAb 957
 - chemotherapeutics 326
 - clinical activities 38
 - clinical development 431
 - conventional chemotherapy 6
 - murine anti-CEA 24
 - peptide receptors 1219
 - radionuclide delivery 411
- monomeric tracer labeling 262
- monomethyl auristatin E (MMAE) 73, 79
 - trigger group 583
- monopalmitoylphosphatidylcholine (MPPC) 1002
- MOPP therapy 25
- motif
 - structural 514
- mouse serum albumin (MSA) 90
- MPEG (methyl PEG) 1106
- mPEG-OH (methoxy poly(ethylene glycol)) 628
- MPEG-HPAE block copolymer 1106
- MPPC (monopalmitoylphosphatidylcholine) 1002
- MRD (minimal residual disease) 466
- MRI (magnetic resonance imaging) 34, 44
 - cellular structure 46
 - hybrid MRI/PET scanner 248
 - lymphotropic nanoparticles 229
 - magnetic nanoparticles 47
 - metabolic response 46
 - theranostic micelles 1062
- MS (mass spectrometry) 887
 - data quantification and normalization 338
 - proteome mapping 336
- MSA (mouse serum albumin) 90
- MSV (multistage vector) 888, 896
 - intracellular trafficking 900
 - schematic illustration 898
- MT1-MMP (membrane type-1 matrix metalloproteinase) 959
- MTD (maximum tolerated dose) 1013
 - CombiPlex® formulations 1032
 - CPX-351 1037
- MTSA (microtubule-stabilizing agents) 24
- MTX (methotrexate) 259, 1312
 - clinical development 789
 - DHA– 1338
 - HSA conjugates 773
 - MTX-loaded dendrimers 534
 - MTX–HSA 862
 - serum proteins 762
- MUC1 1199
- mucosal surfaces 91
- multiagent drug delivery vehicles 1022
- multiagent therapies 808
- multiarm PEG 867
 - structure 844
- multiblock polyHPMAs 267
- multicenter trial 1343
- multidrug resistance (MDR) 34
 - conventional chemotherapy 16
 - CPPs 1194
 - multifunctional pH-sensitive micelles 1117
 - PUFAs 1345
- multidrug-resistant (MDR) tumors 1026
- multifunctional core 278
- multifunctional envelope-type nanodevice (MEND) 1377
 - structure 1378
- multifunctional micellar nanodevices 1064
- multifunctional molecular adapter 1466
- multifunctional pH-sensitive micelles 1114
- multifunctional polymeric drug carriers 249
- multilayer
 - polyelectrolyte 725
- multimerization 1501
- multinodular HCC 873, 1557
- multiple elimination linkers 554

- multiple myeloma 933, 936
 - PLD 935
- multistage vector (MSV) 888
 - intracellular trafficking 900
 - schematic illustration 898
- multivalency 1382
- multiwalled carbon nanotube (MWNT) 546, 1165
 - ADME 1176
 - drug delivery systems 896
- murine γ -retroviruses 1429
- murine anti-CEA monoclonal antibody 24
- murine tumors 3
- mushrooms
 - medicinal 19
- mustard gas 4
- mustine 3
- mutagenesis
 - enhanced 51
- mutations
 - “knob-into-hole” 457
- MX-1 cells 1135
- myeloid cells 36
 - bone marrow-derived 34
- myeloma 952
 - multiple 933, 935, 936
- myelosuppression 18, 1342
 - reversible 25
- Mylotarg® 75, 102, 278, 297
 - calicheamicin ADCs 95
 - New Drug Application 102
- n**
 - N-(2-hydroxypropyl)methacrylamide (HPMA) 66, 108, 110
 - chemical structure 600
 - DOX-DEX 817, 820
 - drug–polymer conjugates 842
 - fluorescently labeled copolymers 247
 - hydrogel-based therapy 1081
 - ligand-assisted vascular targeting 599
 - liver tumor targeting 1551
 - long-circulating copolymer 270
 - multiblock polyHPMAs 267
 - polymer-based combination therapy 814
 - prodrugs 851
 - trigger group 574
 - N-isopropylacrylamide (NIPAAm) 671
 - N-succinyl-chitosan derivatives 722
 - nab-docetaxel 1145
 - nab-paclitaxel 1139
 - clinical studies 1152
 - nab-rapamycin/perifosine 1147
 - naked immunoglobulins 449
 - Nano-PICsomes 1062
 - nanoarchitectures
 - highly ordered 1054
 - nanocapsules
 - photosensitizers 538
 - nanocarriers 887
 - ligand-based 1524
 - pH-sensitive 257
 - solid tumor targeting 1523
 - nanodevices 1361
 - multifunctional envelope-type 1361
 - multifunctional micellar 1064
 - theranostic 1062
 - nanoemulsions
 - dual-drug delivery systems 1027
 - nanogels 1072, 1078, 1122
 - nanoglobular dendrimeric platform 609
 - nanomolar range 1287
 - nanoparticle albumin bound (nab) technologies 761, 895, 1136
 - drug encapsulation 1137
 - product pipeline 1148
 - small-molecule drugs 1139
 - nanoparticles 887
 - active targeting 232
 - albumin 895
 - albumin-conjugated PEGylated 1149
 - albumin–drug 1133
 - cationic lipid 1371
 - chitosan-coated 894
 - clinical studies 1152
 - CombiPlex® formulations 1040
 - core/membrane lipid-based 1376
 - DC-SPION 266
 - delivery 346, 1271
 - DOX 809
 - doxorubicin–HSA 1147
 - drug delivery vehicles 1573
 - drug-encapsulated 1527
 - gene therapy 237
 - inorganic 1272
 - liver tumors 1546
 - lymphotropic 68, 229
 - magnetic 44
 - mitoxantrone-loaded 1547, 1553
 - passive targeting 55
 - polymer 1505
 - Polysorbate 80-coated 1506
 - prodrug 1042
 - SCK 893
 - self-assembled HFT 729
 - siRNA 545
 - solid lipid 1508

- SPION 43, 899, 1089, 1548
- synthetic approaches 759
- targeted therapy 236
- targeting liposomes 124
- transferrin–USPIO 233
- tumor-targeting 16
- nanoparticulate drug delivery systems 887
 - combination chemotherapy 1013
- nanoparticulate pharmaceutical carriers 952
- nanopharmaceuticals 814
- nanorods
 - Au–Ag 1272
- nanosized hydrogels 1072
- nanotechnology
 - medical sciences 887
- nanotubes 887
 - carbon 546, 896, 1163
 - covalent modification 1166, 1178
 - functionalized 1168
 - MWNT 546, 896, 1165
 - noncovalent modification 1167
 - SWNT 896, 1165
- natural killer (NK) cells 449
- natural polymer–drug conjugates 730
- NCT (neutron capture therapy) 539
- NDA (New Drug Application)
 - Mylotarg® 102
- near-IR imaging 38
- necrolysis
 - epidermal 297
- necrosis 1445
- necrosis factor
 - TNF 96
- necrotic areas 16
- needle injection 1405
- neoangiogenesis
 - imaging 260
- neocarcinostatin (NCS) 772, 871
 - hepatotropic delivery 1543, 1555
- neonatal Fc receptor (FcRn) 85
 - altered binding 95
 - antigen presentation 93
 - discovery 87
 - kidneys 94
 - liver 95
 - structure 88, 89
- neonatal immune thrombocytopenia
 - fetal 91
- neoplasms
 - secondary 25
- neoplastic cells 236
- neovasculature endothelial cells 595
- nephrotoxicity 22
- nervous system 281
- networks 1071
 - cross-linked 1071
 - hydrogel 1073
 - interpenetrating 1081
 - microvascular 1003
 - signaling 11
- neuroendocrine cancers 271
- neuroendocrine tumors 270, 281
- neurological side-effects 24
- neurovascular unit 1490
- neutralizing antibodies 1459
- neutron capture therapy (NCT) 539
 - boron 277, 538
- neutropenia 1344
- neutrophil
 - polymorphonuclear 451
- New Drug Application (NDA)
 - Mylotarg® 102
- NHL 103, 203, 294
 - cytotoxic somatostatin analogs 1243
 - immune therapy targeting 449
 - LHRH cytotoxic analogs 1233
- Nile Red 581
- nitric oxide synthase (NOS) 67
- 2-nitroimidazole 268
- nitroglycerin 78
- nitrosylcobalamin 1302
- NK (natural killer) cells 449
- NKTR-102 645, 868
- NKTR-105 639, 655
- NLS (nuclear localization signal) 423
- NO-releasing agents 78
- non-Hodgkin's lymphoma 38, 102, 294
 - cytotoxic somatostatin analogs 1243
 - immune therapy targeting 449
 - LHRH cytotoxic analogs 1233
- non-PEGylated liposomes 907
- non-small-cell lung cancer (NSCLC) 27, 851, 1343, 1349, 1403
 - LipoPlatin 1623
- nonantibody ligands
 - liposome targeting 967
- nonantibody proteins 1580
- noncleavable linkers 71
- noncleavable thioether linkers 269
- noncovalent associations 456
- noncovalent loading 282
- noncovalent modification
 - CNTs 1167
- nondegradable linker 602
- nonenveloped viruses 1433
- nonglycosylated fusion protein 22
- noninvasive molecular imaging 253
- nonlactosaminated albumin 1540

- nonmetabolizable CHE 1041
- nontarget internalization 1208
- nonviral vectors 1058, 1398, 1401
 - subcellular trafficking pathways 1060
- normal tissues
 - microvasculature 38
- normalization
 - MS data 338
- NOS (nitric oxide synthase) 67
- NPC (nuclear pore complex) 247
- NSCLC (non-small-cell lung cancer) 27, 851, 1343, 1349, 1403
 - LipoPlatin 1623
- nu/nu mice 272, 1297
- nuclear delivery
 - hormone-mediated 261
- nuclear localization signal (NLS) 423
- nuclear pore complex (NPC) 247
- nuclease resistance 1275
- nucleic acids 1189
 - delivery 1189
 - locked 1364
 - site-specific delivery 1055
- nucleobase modification 1364
- nucleosome binding 964
- nucleosome-specific antibodies 961
- nucleosomes
 - interaction with AnAs 964
- nucleotide binding 542
- nude mice
 - athymic 1229, 1247
- O**
- O-glycan-peptide signatures 1271
- O₂-sensitive CPP systems 1204
- oasireotide 1237
- OATP (organic anion transporting polypeptide) 1493
- obinutuzumab 449
- OBOC (one-bead/one-compound) libraries 3, 11, 14, 16
- octanol/water partition coefficient 1079
- ODD (oxygen-dependent degradation domain) 1205
- oligomeric BsAbs
 - hetero- 455
- oligonucleotides 542
 - albumin nanoparticle delivery 1150
 - antisense 543
 - delivery 1195
 - PEGylation 656
 - vectorization 1196
- oligosaccharides
 - cyclic 735
- “On”/“Off” systems 1423
- on-demand cleavable linkers 26
- oncaspar 655
- ONCOFID 866
- ONCOFID-P 725, 726, 871
- oncogenes 1199
- oncogenic signaling 1198
- oncology 1415
 - clinical 35
 - dendritic polymers 274
- oncolytic adenoviruses 1431
- Onconase®
 - ranpirnase 1480
- oncoproteins 1199
- one-bead/one-compound (OBOC) libraries 4, 12, 14, 16
- Ontak® 1472
- ONYX-015 1400, 1403
- Opaxio 830, 857
 - structure 810
 - tumor uptake 842
- optical imaging 200
- optimal dose schedule
 - PLD 938
- optimal linker selection 381
- optimization
 - ligand 22
- oral delivery 721
- ordered nanoarchitectures 1054
- organ-specific targeting
 - platinum complexes 1612
- organic anion transporting polypeptide (OATP) 1493
- organs
 - penetration 415
- osteosarcoma 1614
- osteosclerotic bone metastases 278
- ovarian cancer 925
 - cytotoxic somatostatin analogs 1240
 - LHRH cytotoxic analogs 1230
 - PLD 927
 - ProLindac 854
- ovarian tumor xenografts 1467
- overexpression
 - SPARC 1144
- oxaliplatin 1605
 - liposomal encapsulated 1619
 - oxaliplatin–tamoxifen 1612
- oxidative activation 569
- oxycarbonyl group 558
- oxygen species
 - reactive 1328, 1331, 1569

- oxygen-dependent degradation domain (ODD) 1205
- oxygenation
 - pretherapeutic 268
- ozogamicin
 - gemtuzumab 276
- p**
- P-glycoprotein 1493
 - inhibition 1498
- P-glycoprotein (P-gp) 612
- P-glycoprotein efflux effect 965
- P-gp+ DLD1 human colon tumor xenograft 1346
- p16 1201
- p21 1202, 1207
- p21 mimetic peptide 685
- p27 1202
- P450
 - cytochrome 1349
- p53 1200
- PACA (polyacrylcianoacrylate) 1527
- paclitaxel 258
 - aerosolized liposomal 970
 - antitumor activity 1340
 - brain targeting 1497
 - DHA– 1338
 - ester linkage 638
 - heparin–folic acid–PTX 729
 - HMPA– 852
 - hydrogel-based therapy 1079
 - ligand-assisted vascular targeting 606
 - nab- 1139
 - PEG–Gly–paclitaxel 641
 - PEG–paclitaxel derivatives 640
 - poly(glutamic acid)-bound 554
 - polyglycerol–paclitaxel complex 522
 - polymer-based combination therapy 807
 - polysaccharide–drug conjugation 713
 - prodrug nanoparticles 1042
 - PUFAs 1332
 - second-generation taxoid conjugates 1345
 - transcytosis 1140, 1141
- paclitaxel prodrugs
 - elimination 1042
- paclitaxel/gemcitabine 1043
- paclitaxel–PGA conjugate 840
- palliative treatment 13
- palmar–plantar erythrodysesthesia (PPE) 915, 916, 934
- PAMAM (poly(amidoamine)) 270, 279
 - boronated 538
 - diagnostic application 541
- Panc-1 pancreatic tumor xenograft 1348
- pancreatic cancers 1219
 - cytotoxic somatostatin analogs 1219
 - LHRH cytotoxic analogs 1234
- pancreatic tumor
 - human 1034
- particle bombardment 1371, 1401
- particle formation
 - interlipidic 1005
- PAsp(DET) (poly(N-(N-(2-aminoethyl)-2-aminoethyl)aspartamide)) 1059
- passive carriers 1575
- passive targeting 639
 - CPPs 1203
 - nanoparticles 55
 - platinum complexes 1616
- pathophysiological characteristics
 - solid tumors 65, 667
- pathophysiological microenvironment 48
- pathophysiology 952
 - receptor 33
 - tumors 782
- patient self-assessment questionnaire 921
- PBAVE 1376
- PBCA (poly(butyl cyanoacrylate)) 1505
- PBS (phosphate-buffered saline) vehicle control 468
- PCI (photochemical internalization) 1589, 1590
- PCL (poly(3-caprolactone)) 612
- PCR (polymerase chain reaction) 1416
- PDEPT (polymer-directed enzyme prodrug therapy) 812, 813
- pDNA (plasmid DNA) 1367, 1407
- PDP (pyridyldithiopropionate) 956
- PDT (photodynamic therapy) 277, 537, 1149
 - clinical developments 1591
 - drug delivery vehicles 1576
 - growth factor targeted delivery 1311
 - hydrogel-based 1087
 - targeting and delivery 1569, 1573
- PDZ 1459
- PE (Pseudomonas aeruginosa exotoxin A) 34
 - clinical trials 1474
 - targeted 1448, 1460
- pectin–drug conjugates 732
- PEG (poly(ethylene glycol)) 1053
 - palisade 1053
 - pH-triggered micelles 1103
 - prodrugs 855
 - surface-grafted chains 992
 - toxicity profile 628
 - U-PEG 633
- PEG dilemma 79
- PEG-aldehyde linker 632

- PEG-coated SWNTs
 - biodistribution 1176
- PEG-derivatized lipids 1372
- PEG-detachable systems 1059
- PEGA (poly(ethylene glycol) acrylamide) 19
- pegfilgrastim 633
- peginterferon- α 2a 634
- PEGylated antibody fragments 634
- PEGylated CPP–liposomes 1205
- PEGylated liposomal doxorubicin (PLD) 909
 - breast cancer 916, 930
 - economic analysis 936
 - multiple myeloma 935
 - optimal dose schedule 938
 - ovarian cancer 927
 - pharmacokinetics 912
 - radiolabeled 920
 - targeting 910
- PEGylated liposomes 891
 - brain targeting 1502
 - cisplatin 939
 - derivatization 955
 - development 952
 - doxorubicin (DOX) 953
 - dual-drug delivery systems 1026
 - EGFR 940
 - newer applications 939
 - radiolabeled 920
 - targeting 910
 - toxicity profile 915
- PEGylated nanoparticles
 - albumin-conjugated 1149
- PEGylation 627
 - CNTs 1173
 - oligonucleotides 656
 - permanent 630
 - polyplexes 1059
 - releasable 638
 - site-specific 628
 - targeted toxins 1460
- PEG–Ara-C 652, 653
- PEG–camptothecin analogs 641
- PEG–drug conjugates 627
 - acid-activated 651
 - clinical trials 653, 654
 - hydrolyzable 844
 - pharmacokinetics 636
- PEG–Gly–paclitaxel 641
- PEG–lipid conjugates 955
- PEG–paclitaxel derivatives 640
- PEG–phospholipid conjugates 1001
- PEG–TSCA conjugates 610
- PEI (polyethylenimine) 615
- PEI (polyethylenimide) 1373
- PEI (polyethylenimine) 1137
- PELT (polymer enzyme liposome therapy) 812
- PEM (polyelectrolyte multilayer) 725
- Pen-ELP-H1 989
 - antiproliferative effect 686
 - c-Myc inhibitor 687
- Pen-ELP1-H1 685
- penetration 989
 - cell 989
 - nanocarriers 991
 - rapid 1276
 - triggerable 995
- pentaheptad peptides 268
- PEO (poly(ethylene oxide)) 673
- Pep-3 1197
- peptide conjugates
 - PDT 1579, 1581
- peptide hormone–drug conjugates 150
- peptide ligand–drug conjugates 4
- peptide linker
 - enzymatically cleavable 784
- peptide nucleic acid (PNA) 1591
- peptide receptor radionuclide therapy (PRRT) 272
- peptide-based spacers 1288
- peptide-binding groove 88
- peptide-mediated delivery 610
- peptides 5
 - amphipathic 1197
 - bombesin/gastrin-releasing 1244
 - cancer-targeting 3
 - cell penetrating 1113
 - cell-penetrating 680, 1189, 1443, 1456
 - CREKA 1149
 - delivery 682
 - drugs 1082
 - homing 1203, 1207
 - iRGD 1057
 - p21 mimetic 685
 - pentaheptad 268
 - PHSCN 545
 - radiolabeling 418
 - receptors 1219
 - RGD 102, 255, 262, 263
 - RGD4C 1117
 - targeted cytotoxic analogs 1220
 - targeting ligands 1382
 - TAT 995
 - therapeutic 684
 - Trojan 1447
 - tumor-homing 1149
 - vasoactive intestinal 968
- peptidic linkers 79

- peptidomimetics 4
 - ligand LLP2A 23
- peptidyl linker 708
- perfusion 1489
 - arteriovenous shunt 37
 - tumors 46
- pericytes 1491
- perifosine 1147
- peripherally inserted central catheter (PICC) 6
- perivascular distribution
 - doxorubicin 17
- permanent linkages 628
- permanent PEGylation 630
- permeability 951
 - EPR 85, 251, 326, 639, 952, 1194, 1203
 - liposomes 999
 - vascular factors 66
- peroxidation
 - PUFAs 1331
- peroxynitrite 72
- persistence
 - biologic 1169
- personalized therapeutics 16, 793
- PET (positron emission tomography) 28
 - CNTs 1179
 - drug design 275
 - functional and molecular imaging 249
 - image generation 416
 - immunoPET 418, 431
 - radiation treatment planning 275
 - radionuclide delivery 414, 415
 - radiopharmaceuticals 251
 - tracers 251
 - tumor imaging 34
- PET/CT 247
 - biomarkers 250
 - clinical applications 272
 - preclinical imaging 258
- PFS (progression-free survival) 1039, 1154
- PGA (poly(glutamic acid)) 3
 - clinical trials 858
 - drug–polymer conjugates 839, 857
 - prodrugs 857
- pGHRH-R 1248
- pH
 - human tumor xenografts 1101
- pH dependence
 - antitumor drugs 56
- pH-dependent activation 569
- pH-dependent deshielding 1203
- pH-responsive linker systems 1298
- pH-sensitive copolymer 1205
- pH-sensitive CPP systems 1204
- pH-sensitive micelles 1099
 - multifunctional 1099
 - polymeric 1054, 1108
 - tumor delivery 1099
- pH-sensitive nanocarriers 257
- pH-sensitive pullulan–DOX conjugate 731
- pH-triggered drug release 1104
 - endocytic 1115
- pH-triggered exposure of TAT 1113
- pH-triggered interfacial defects 998
- pH-triggered modulation
 - micelle surface functionality 1113
- phage-display libraries 3
 - growth factor targeted delivery 1313
 - tissue-specific targets 335
- phages
 - tumor cell-targeting 12, 14
- phagocytosis
 - frustrated 1172
- pharmaceutical carriers 951
 - nanoparticulate 951, 952
 - site-specific 951
- pharmacokinetics 36, 85
 - ADCs 300
 - AMCs 379
 - AN-152 1235
 - CNTs 1170, 1173
 - combination chemotherapy 1020
 - dendrimers 249
 - dendritic architecture 535
 - DOX 790, 914
 - DOXO-EMCH 790
 - FcRn 95
 - liposomes 970
 - nab-paclitaxel 1152
 - PEG–drug conjugates 636
 - PLD 912, 914
 - sterically stabilized liposomes 913
 - TXP 1339
- pharmacology
 - preclinical 1030, 1033, 1035, 1289
- phase I trials 1013
 - CPX-1 1013
 - TXP 1342
- phase II trials
 - CPX-1 1039
- phase II/III trials
 - TXP 1343
- phase transition
 - temperature-triggered 672
- HEMA (poly(hydroxyethyl methacrylate)) 1072, 1089
- phenyl ring 560
- phenylazides 567

- PhiPhiLux 532
- phosphate-buffered saline (PBS) vehicle control 468
- phosphatidylcholine–cholesterol–PEG2000–DSPE liposomes 1026
- phosphatidylinositol 3-kinase 1416
- phospholipid dispersions 889
- phospholipids 1361
 - anionic 1361
 - maleimide-carrying 969
 - PEG–phospholipid conjugates 1001
 - photoisomerizable 1004
 - PUFAs 1326
 - synthesis 250
- phosphorylation 1365
- phosphoramidate prodrugs 560
- photoacoustic imaging 1180
- photochemical activation 572
- photochemical internalization (PCI) 1589, 1590
- photochemistry 1569
- photodynamic molecular beacon (PMB) 1588
- photodynamic therapy (PDT) 277, 537, 1149
 - clinical developments 1591
 - drug delivery vehicles 1576
 - growth factor targeted delivery 1311
 - hydrogel-based 1087
 - targeting and delivery 1569, 1573
- photoimmunoconjugate (PIC) 1577
- photoisomerizable phospholipid 1004
- photomultiplier tubes (PMTs) 258
- photophysics 1569
- photopolymerization 1077
- photosensitizer-linker-mAb conjugates
 - indirect 1578
- photosensitizers 247, 1080, 1087, 1149, 1571
 - enzyme-cleavable conjugates 1586
 - ideal 1571
 - mAb–photosensitizer conjugates 1577
 - macromolecular 1585
 - nanocapsules 538
 - polymer–photosensitizer conjugates 1584, 1586
 - protein–photosensitizer conjugates 1583
 - small-molecule–photosensitizer conjugates 1588, 1589
 - structure 1572
 - targeting via antibodies 1575
- PHSCN peptide 545
- phthalocyanine-encapsulated polymeric micelle
 - dendrimer 537
- phthalocyanines 1571
- physical conjugation 1271
- physical cross-linking 1074
- physicochemical characterization
 - combination therapy 816
- physiological pH 1059
- PIC (polyion complex) micelles 1058
- PICC (peripherally inserted central catheter) 6
- PICsomes 1061
- pIgR (polymeric immunoglobulin receptor) 91
- PIHCA 1546, 1547, 1553
- pinocytosis
 - fluid-phase 1114
- PIONEER 859, 876
- pirarubicin 73
- pirarubicin micelles
 - SMA– 75
- PK1 843
- PK2 1551
 - hepatotropic delivery 1529
 - structure 1532
- placental transport
 - directional 90
- planar g-scintigraphy 85
- plant RIPs 1451
- plant toxins 1464, 1466
- plasma cholesterol 753
- plasma clearance 379
- plasma elimination 1043
- plasma proteins 748
- plasmid DNA (pDNA) 1367, 1407
- plasmid expression
 - shRNA 1418
- plasmid-derived shRNAs 1420
- plasmids encoding GFP 995
- plasmon resonance
 - surface 112
- platinophiles 1609
- platinum complexes 839
 - antineoplastic 839
 - liposomal drug delivery 1616
 - targeting strategies 1605
- platinum-based combination chemotherapies 37
- platinum-refractory tumors 928
- platinumphosphonate complexes 1615
 - structure 1616
- platinum–DNA adducts 1035
- PLD (PEGylated liposomal doxorubicin) 909
 - breast cancer 916, 930
 - economic analysis 936
 - multiple myeloma 935
 - optimal dose schedule 938

- ovarian cancer 927
- pharmacokinetics 912
- radiolabeled 920
- targeting 910
- PLLA (poly(L-lactic acid)) 674, 1105
- Pluronic 675
- PMB (photodynamic molecular beacon) 1588
- PMN (polymorphonuclear neutrophil) 451
- PMTs (photomultiplier tubes) 258
- PNA (peptide nucleic acid) 1591
- PNiPAAm 1077
- Pol III promoter 1419
- poloxamers 675, 676
- poly(β -amino esters) (HPAE) 1106
- poly(3-caprolactone) (PCL) 612
- poly(amidoamine) (PAMAM) 270, 279
 - boronated 538
 - diagnostic application 541
- poly(butyl cyanoacrylate) (PBCA) 1505
- poly(ϵ -caprolactone) spacer 257
- poly(ethylene glycol) (PEG) 1053
 - drug conjugates 1053
 - palisade 1059
 - PEG-aldehyde linker 632
 - PEGylation 627, 628
 - PEG–camptothecin analogs 641
 - PEG–CPT 855, 856
 - pH-triggered micelles 1103
 - polymer-based combination therapy 817
 - SC-PEG 631
 - SS-PEG 630
 - surface-grafted chains 992
 - toxicity profile 628
 - U-PEG 633
- poly(ethylene glycol) acrylamide (PEGA) 19
- poly(ethylene oxide) (PEO) 673
- poly(glutamic acid) (PGA) 839
 - clinical trials 839
 - drug–polymer conjugates 839, 857
 - prodrugs 857
- poly(glutamic acid)-bound paclitaxel 554
- poly(hydroxyethyl methacrylate) (PHEMA) 1072, 1089
- poly(L-glutamic acid) (PGA) 3
- poly(L-histidine)
 - interfacial 1121
- poly(L-lactic acid) (PLLA) 674, 1105
- poly(N-(N-(2-aminoethyl)-2-aminoethyl) aspartamide) (PAsp(DET)) 1059
- poly(N-isopropylacrylamide) (PNiPAAm) 671, 1077
 - chemotherapeutics 674
- poly(organophosphazene) (PPZ) 677
- poly(propylene oxide) (PPO) 673
- polyacetal polymers
 - biodegradable 844
- polyacids 1103
- polyacrylycyanoacrylate (PACA) 1527
- polyarginine 1210
- polybases 1103
- polycation
 - cyclodextrin-containing 1375
- polyconjugates
 - schematic formation 1376
- polyelectrolyte multilayer (PEM) 725
- polyethyleneimine (PEI) 615, 1137, 1373
- polygalactosamine–drug conjugates 735
- polyglycerol
 - dendritic 527
- polyglycerolamine 544
 - dendritic 543
- polyglycerol–DOX prodrugs 536
- polyglycerol–paclitaxel complex
 - hydrophobic 522
- polyion complex (PIC) micelles 1058
- polylysine backbone 1587
- polymer carriers 99
 - backbone degradable 263
 - drug binding 250
 - efficiency 104
 - long-circulating 264
- polymer enzyme liposome therapy (PELT) 812
- polymer nanoparticles 1505
- polymer peptide–drug conjugate 150
- polymer therapeutics 262, 591, 701
 - APN-targeted 613
 - endothelial cell-targeted 597
 - targeted 599
- polymer vesicles 1054
- polymer-based combination therapy 805
 - clinical development 816
 - EPR effect 810
 - preclinical development 817
 - target sites 811
- polymer-based systems 89, 1053
- polymer-directed enzyme prodrug therapy (PDEPT) 812, 813
- polymerase chain reaction (PCR) 1416
- polymeric carriers
 - polymer-based combination therapy 812
- polymeric delivery systems 1619
- polymeric immunoglobulin receptor (pIgR) 91
- polymeric micelles 892, 1054
 - brain targeting 1508

- polymeric micelles (*contd.*)
 - dendrimer phthalocyanine-encapsulated 537
 - dual-drug delivery systems 1027
 - pH-sensitive 1054, 1108
 - smart 1054
 - TAT-conjugated 1114
- polymeric photosensitizer prodrug (PPP) 1587
- polymers 1071
 - amphiphilic 627, 1078
 - biodegradable 739, 844
 - carriers 839, 841
 - cascade 540
 - cationic 1373
 - cross-linked network 1071
 - dendritic 274
 - histidine-derived 1105
 - hydrogel networks 1073
 - hydrogel-based prodrugs 1081
 - hydrolysis 840
 - imidazole-containing 1119
 - interpenetrating network 1081
 - liposome-membrane-incorporated 966
 - mAb–photosensitizer conjugates 1578
 - melamine 536
 - protective 955
 - self-immolative comb 580
 - smart 1074
 - stimuli-sensitive 668, 1074
 - synthetic 671, 953
 - thermo-responsive 667
 - titratable 999
- polymersomes 1054, 1061
 - drug release 1061
- polymer–drug conjugates 34, 707
 - combination therapy 810
 - combined with radiotherapy 830
 - design 89
 - natural 730
 - polymer-based combination therapy 818
 - RGD-based 601
 - selectin-targeted 612
 - water-soluble 272
- polymer–photosensitizer conjugates 1584, 1586
- polymorphoneutrophils 1570
- polymorphonuclear neutrophil (PMN) 451
- polypeptides 1071
 - Bac-ELP-p21 688
 - elastin-like 678
 - polypeptide–drug conjugate 671
- polyphosphazene 1082
- polyplexes 1373
 - PEGylation 1059
 - schematic formation 1374
- polysaccharide-based drug conjugates 747
- polysaccharides 1133
 - Chemical structure 702
 - hydroxyl groups 711
- polysaccharide–drug conjugates
 - synthesis 708
- polysaccharide–drug conjugation 707
- Polysorbate 80-coated nanoparticles 1506
- polysorbate-based docetaxel 1141, 1154
- polyunsaturated fatty acids (PUFAs) 1359
 - internalization 1325
 - second-generation taxoid conjugates 1345
- POMP regimen 12
- pop-up mechanism
 - versatile tumor targeting 1121
- pore complex
 - nuclear 247
- pores 989
 - transbilayer 989
 - transmembrane 1000
- porosification of silicon 897
- porous silicon microparticles
 - diskoidal 899
- positron emission tomography (PET) 27
 - CNTs 1179
 - drug design 275
 - image generation 416
 - immunoPET 418, 431
 - PET/CT 247
 - radiation treatment planning 275
 - radionuclide delivery 414, 415
 - radiopharmaceuticals 251
 - tracers 251
 - tumor imaging 34
- positron emitters 417
 - immunoPET 418
- postcapillary venules 69
- PPD modification 1378
- PPE (palmar–plantar erythrodysesthesia) 915, 916, 934
- PPO (poly(propylene oxide)) 673
- PPP (polymeric photosensitizer prodrug) 1587
- PPZ (poly(organophosphazene)) 677
- PrAgU2 1465
- Prato reaction 1166
- pre-antibody era 442
- preclinical development 1219
 - bombesin/gastrin-releasing peptides 1219
 - CombiPlex® formulations 1030
 - cytotoxic somatostatin analogs 1236

- GHRH antagonists 1247
- hepatotropic drug delivery systems 1528
- LHRH cytotoxic analogs 1221
- PDT 1573
- polymer-based combination therapy 817
- responsive liposomes 994
- targeted toxins 1462
- preclinical evaluations 1359
 - cross-species binding 112
 - TXP 1338
- preclinical imaging 805
 - SPECT/CT and PET/CT 258
 - tumors 247
- preclinical models
 - combination therapy 815
- preclinical pharmacology 1013
 - CPX-1 1033
 - CPX-351 1030
 - CPX-571 1013
 - FA–drug conjugates 1289
- preclinical studies 1053
 - micellar structures 1053
 - second-generation taxoid conjugates 1345
- precontrast 230
- predetermined breaking point 555, 874
- preparation
 - antibody-targeted liposomal drugs 968
- pretargeting 429
 - receptors 541
- pretherapeutic detection
 - metastases 275
- pretherapeutic tumor oxygenation 268
- pretherapy biodistribution 434
- prevascular growth phase 34
- primary bone tumors 1614
- pristine SWNTs 1175
- pro-inflammatory cytokines 894
- pro-prodrugs 556
- proapoptotic proteins 1228
- probes 1489
 - fluorescent 541
 - molecular imaging 44
- prodrugs 1163
 - and drugs 20
 - brain targeting 1495
 - calicheamicin 75
 - cholesterol paclitaxel 1042
 - dual-acting 784, 787, 878
 - enzymatically cleavable 527, 562
 - enzyme prodrug systems 4
 - GDEPT 1397
 - HepDirect™ 1527, 1529
 - HPMa 851
 - hydrogel-based 1081
 - in situ binding 779
 - macromolecular 251, 755, 782
 - paclitaxel 1042
 - PDEPT 812, 813
 - PEG 855
 - PGA 857
 - phosphoramidate 560
 - polyglycerol–DOX 536
 - polymeric photosensitizer 1587
 - site-specific activation 591
 - tripartate 556
- product pipeline
 - nab technologies 1148
- products
 - double-prodrug concept 556
- progenitor cells
 - hematopoietic 1430
- progeny virus 1426
- prognostic potential
 - imaging biomarkers 273
- progression
 - cancer 1324
- progression-free survival (PFS) 1039, 1154
- progressive acidification 991
- proliferating endothelial cells 592
- proliferation 35
 - cellular 35, 685
 - liver cancer 1551
- proliferative activity 264
- proliferative factors 1419
- ProLindac 1619
 - clinical development 1625
 - drug–polymer conjugates 853
 - partial structure 1621
- promoter
 - Pol III 1419
- propofol 1335
- prostate cancer 11
 - cytotoxic somatostatin analogs 1240
 - LHRH cytotoxic analogs 1230, 1232
- prostate-specific antigen (PSA) 562
- prostate-specific membrane antigen (PSMA) 295, 1265
 - siRNA 1274
- protamine 1198
- proteases 79, 1586
 - protease-dependent activation 1203
 - upregulation 554
- protective polymers 955
- protein toxin 1310
- protein transduction domain (PTD) 1381, 1447
 - TAT 1456
- protein-based delivery system 1151

- protein-based drugs 103
 - protein-coupled liposomes 1504
 - proteins 1489
 - ABC export 1489
 - albumin nanoparticle delivery 1150
 - angiogenic 35
 - angiotensin-converting 341
 - Antennapedia 1189
 - antiapoptotic 1228
 - ASGP 730
 - biosynthesis imaging 257
 - conjugation with SC-PEG 632
 - conjugation with SS-PEG 630
 - drugs 1082
 - E1B-55K 1432
 - FABP 1325, 1326
 - fluorescein isothiocyanate-labeled 757
 - GFP 262, 1198, 1421
 - human 1468
 - IAP 1200
 - MDR-1 1221
 - nonantibody 1580
 - nonglycosylated fusion 22
 - plasma 748
 - proapoptotic 1228
 - purified 1265
 - radiolabeling 418
 - recombinant fusion 1457
 - reductive alkylation 633
 - RIP 1451, 1452, 1475
 - serum 747
 - targeted toxins 1443
 - targeting ligands 1382
 - tumor suppressor Rb 687
 - vitamin B12-binding 1300
 - von Hippel-Lindau 65
 - protein–photosensitizer conjugates 1583
 - proteoglycan NG2 460, 468
 - proteolytic activation 564
 - proteolytic degradation 92, 96
 - proteome 337
 - alterations 49
 - human serum 747
 - vascular endothelial cells 336
 - proton sponge effect 1059, 1118, 1375
 - protonation of histidine moieties 1125
 - PRRT (peptide receptor radionuclide therapy) 272
 - PSA (prostate-specific antigen) 562
 - PSCA-specific diabodies 430
 - Pseudomonas aeruginosa* exotoxin A (PE) 111
 - clinical trials 1474
 - targeted 1448, 1460
 - Pseudomonas* toxin 13
 - PSMA (prostate-specific membrane antigen) 295, 1265
 - siRNA 1274
 - PTD-DRBD 1198
 - PUFA–chlorambucil 1336
 - PUFA–drug conjugates 1359
 - gene expression 1328
 - PUFA peroxidation 1331
 - signal transduction pathways 1328
 - structure 1333
 - PUFA–mitomycin C 1336
 - PUFA–taxoid conjugates 1346
 - PUFA–tegafur 1337
 - pullulan–drug conjugates 729
 - pulmonary side-effects 22
 - pumping
 - transvascular 329
 - purification of ELPs 680
 - purified proteins 1265
 - pyridoxine 1307
 - pyridyldithiopropionate (PDP) 956
 - pyrimidine
 - fluorinated 1032
 - pyrrolidine 1176
 - 2-pyrrolino-DOX 1225
 - structure 1246
 - pyrrolic ring systems
 - conjugated 1571
- q**
- QD–photosensitizer hybrids 1575
 - quantification
 - MS data 338
 - quantum dots (QD) 1574
 - quenching
 - self- 1587
 - quercetin 1027
 - quinone methide elimination 559
- r**
- radiation treatment planning 275
 - radioactive decay products 420
 - radioactive immunoconjugates 77
 - radioactive nonmetabolizable CHE 1041
 - radiofrequency tumor ablation 971
 - radioimmunoconjugate 27
 - radioimmunoimaging
 - clinical development 431
 - radioimmunoscintigraphy agents 417
 - radioimmunotherapy (RIT) 266, 411, 1206
 - clinical development 434
 - radioiodinated LHRH 1225
 - radiolabeled antibodies 412

- radiolabeled bombesin analogs 1245
- radiolabeled CNTs 1176
- radiolabeled integrin antagonists 262
- radiolabeled LDL 757
- radiolabeled PEGylated liposomes 920
- radiolabeled PLD 920
- radiolabeled transferrin 753
- radiolabeling
 - in situ 333
- radiometals 421
- radionuclides 1189
 - delivery 411, 1189
 - g imaging 417
 - imaging 415
 - PRRT 272
 - theranostics 435
 - therapeutic 418, 419
- radiopeptide therapy 271
- radiopharmaceuticals 251, 259
- radiotherapy 805
 - combined with polymer–drug conjugates 805
 - growth factor targeted delivery 1311
 - hydrogel-based 1088
 - polymer-based combination therapy 812
 - targeted 414, 1238
- radiotracers 34, 36
 - hypoxia-selective 267
- random coil conformation 247
- ranpirnase
 - Onconase® 1480
- rapamycin 1432
- rapid amplification of cDNA ends (RACE) 1418
- rapid penetration 1276
- ratio-dependent synergy 1016, 1031
 - In vitro evidence 1017
- ratiometric dosing platform 1040
- ratios
 - drug 1014
- rats
 - Sprague-Dawley 693
- Rb (tumor suppressor protein) 687
- RCC (renal cell carcinoma) 1223
 - cytotoxic somatostatin analogs 1241
 - LHRH cytotoxic analogs 1232
- reactive agents
 - CombiPlex® formulations 1033
- reactive oxygen species (ROS) 1328, 1331, 1569
- reactivity
 - cell-targeting 993
- realizing 759
- receptor-independent endocytosis 1122
- receptor-mediated endocytosis 1115, 1269
- receptor-mediated uptake of LDL 751
- receptors 1519
 - ASGP 840
 - bombesin/gastrin-releasing peptides 1244
 - epidermal growth factor 533, 940, 958, 1313
 - estrogen 807
 - expression imaging 269
 - folate 235, 1119, 1284
 - GHRH 1247
 - gp60 792, 1134
 - hyaluronic acid binding 598
 - LHRH 1221
 - neonatal Fc 85
 - pathologies 33
 - peptides 1219
 - pIgR 91
 - pretargeting 541
 - PRRT 272
 - receptor/antigen targeting 786
 - RHAMM 724
 - somatostatin 34, 270, 1236
 - steroid hormone 261
 - toll-like 1277, 1367
 - transferrin 960, 966
 - tumor-specific 1444
 - tumoral 1222
 - VEGF 261
- recombinant AAV vectors 1434
- recombinant bispecific molecules 457
 - clinical trials 464
- recombinant DNA techniques 27, 88, 695
- recombinant factor VIIa 103
- recombinant fusion proteins 1457
- recombinant IgG-like BsAb 460
- recurrence 274
- recycling 1053
 - blocking 102
 - FcRn-mediated 92
- red blood cells
 - artificial 1062
- redirected lysis 451
- reduced folate carrier (RFC) 1284
- reduction of disulfide bonds 1002
- reductive activation 566
- reductive alkylation 633
- reductive cleavage 25
- reductive environment 1291
- reductive release 1306
- regioisomers 1312
- regulation of gene expression
 - differential 49
- releasable β -ligand conjugates 1301

- releasable dual-drug conjugates 1295
- releasable linkages 628
- releasable PEG linkers 1099
 - aliphatic systems 649
 - aromatic systems 646
- releasable PEGylation 638
- release 1099
 - cytosolic 1099
 - dual-phase mechanism 844
 - endocytic 1115
 - endosomal 1367
 - from polymersomes 1061
 - intracellular 1286
 - IR/UV-activated 1003
 - magnetic field-activated 1006
 - pH-triggered 1104
 - reductive 1306
 - responsive 994
 - slow-release mechanism 1341
 - triggered 996
 - ultrasound-activated 1005
- remodeling
 - matrix 35
- renal cell carcinoma (RCC) 1223
 - cytotoxic somatostatin analogs 1241
 - LHRH cytotoxic analogs 1232
- renal clearance 629
 - threshold 94, 856
- repetitive growth
 - molecular structure 274
- replication of viruses 1432
- repulsion
 - electrostatic 996
- resistance
 - multidrug 16, 34, 1117, 1194, 1345
 - nuclease 1275
- resonance energy transfer
 - fluorescence 249
- respective delivery concept 1446, 1607
- respiratory distress syndrome 23
- response 989
 - inhibitory 774
 - metabolic 46
 - RECIST 34
 - to therapy 274
- responsive liposomes 989
 - preclinical development 989
 - solid tumor therapy 989
- responsive release 994
- restaging 274
- retargeting 450
 - T-cell 464
- retention
 - EPR 85, 251, 326, 639, 952, 1194, 1203
 - retention time in target tissue 1276
- reticuloendothelial system 909
- reticuloendothelial system (RES) 992
 - liver tumors 1527
- retro-aldol–retro-Michael tandem reaction 566
- retro-synthetic analysis 1288
- retroviral vectors 1392, 1400
 - shRNA delivery 1428
- γ -retroviruses
 - murine 1429
- reverse transcriptase
 - human telomerase 1591
- reversible myelosuppression 177
- reversible systems 1423
- RGD peptides 148, 262, 263
 - structure 255
- RGD sequence 1382
- RGD-based polymer–drug conjugates 601
- RGD-based vehicles
 - cyclic 608
- RGD4C 1117
- RHAMM (receptor for hyaluronic acid-mediated motility) 724
- rhodamine-labeled Bac-ELP1-H1 695
- ribosomal display technologies 423
- ribosome-inactivating protein (RIP) 1452
 - clinical trials 1475
 - plant 1451
- ricin 1453
- rigidity
 - membranes 993
- ring
 - phenyl 560
- ring closure
 - spontaneous 557
- ring systems
 - conjugated pyrrolic 1571
- RIT (radioimmunotherapy) 266, 411
 - clinical development 434
- rituximab 444
- RNA 1263
 - aptamer–chimeric 1263
 - artificial micro- 1421
 - chemical vectors 1371
 - conditional systems 1422
 - delivery 1361, 1368
 - ectopic 1368
 - micro- 1361, 1421
 - small interfering 542, 545, 609, 899, 1058, 1085, 1273, 1361, 1379
- RNA interference (RNAi) 1197
 - clinical trials 1417
 - viral vectors 1415

- RNAi drugs
 - clinical trials 1384
- Rnase
 - targeted 1470
- ROS (reactive oxygen species) 1328, 1331, 1569
- RRM2 1385
- S**
 - safety
 - drug 251
 - safety pharmacology assessment 109
 - safety studies
 - CNTs 1171
 - Salmonella 1401
 - saponinum album 1468
 - saporin-based targeted toxins 1456
 - SAR (structure–activity relationship) 18
 - sarcomas 952
 - Kaposi's 919, 922
 - soft-tissue 937
 - Yoshida 54
 - saturation of endogenous silencing pathway 1368
 - SC-PEG (succinimidyl carbonate PEG) 631
 - scaffolds 1415
 - alternative 310
 - dendritic 275
 - SCC (squamous cell carcinomas) 40
 - scDb (single-chain diabodies) 105
 - scFv (single-chain Fv) 452, 459
 - scFv–Fc fragments 425, 426
 - SCID (severe combined immunodeficiency disorder) 1429
 - SCID mice 105, 472, 1348
 - SCK (shell cross-linked knedel) 892
 - nanoparticles 893
 - screening 1359
 - drug–drug interaction 1349
 - dual-color method 20
 - phage-display libraries 6
 - virtual 1313
 - second generation drug–polymer conjugates 865
 - second-generation PEG linker 631
 - second-generation taxoid conjugates 1332, 1345
 - LA/LNA– 1349
 - second-line chemotherapy 13
 - secondary neoplasms 25
 - secondary structure
 - aptamers 1264
 - secreted protein, acidic and rich in cysteine (SPARC) 782, 1135, 1323
 - nab-paclitaxel 1155
 - overexpression 1144
 - selectin 596
 - selectin-targeted polymer–drug conjugates 612
 - selection
 - optimal linkers 381
 - SELEX (systematic evolution of ligands by exponential enrichment) 1264, 1265, 1381
 - self-assembly 1071
 - amphiphilic polymers 1071
 - block copolymers 1054
 - HFT nanoparticles 729
 - lipids 990
 - micellar structures 611
 - self-assessment questionnaire
 - patient 921
 - self-immolation 591
 - complex architectures 573
 - self-immolative comb polymer 580
 - self-immolative dendrimers 575
 - drug release 577
 - self-immolative linkers (SILs) 553, 1288
 - acyclization-based 556
 - clinical application 582
 - self-immolative polymers
 - microcapsules 581
 - self-immolative spacers 5, 25
 - self-quenching 1587
 - sensor
 - apoptotic 532
 - sentinel lymph node (SLN) mapping 247
 - SPECT/CT 276
 - sequence variation 444
 - sequential transcytosis 342
 - serum albumin 85
 - anticancer agents 763
 - bovine 566, 1123
 - half-life 107
 - human 750, 862, 1133, 1323
 - mouse 90
 - structure 86
 - targeting 102, 105
 - zzz 763
 - serum albumin fusion technology 102, 104
 - serum bilirubin 99
 - serum proteins 747
 - clinical development 788
 - serum proteome
 - human 747
 - serum testosterone level 1086
 - severe combined immunodeficiency disorder (SCID) 1429
 - SCID mice 103, 472, 1348

- shell
 - core–shell structure 1058
- shell (corona) 1103
- shell cross-linked knedel (SCK) 892
 - nanoparticles 893
- shielding/deshielding mechanism 1115
- short hairpin RNA (shRNA) 1391, 1406
 - plasmid expression 1418
 - plasmid-derived 1420
 - steric hindrance 1425
- SHR (steroid hormone receptor) 261
- shunt perfusion
 - arteriovenous 40
- sialoglycoprotein 96
- side-chains
 - hydrophobic 272
- side-effects 1359
 - conventional chemotherapy 16
 - neurological 24
 - pulmonary 22
 - vascular 23
- signal transduction pathways 1328
- signaling 1189
 - cytoplasmic region 88
 - networks 24
 - oncogenic 1198
 - PUFA–drug conjugates 1325
- silencing pathway
 - endogenous 1368
- silica particles
 - colloidal 333
- silicon
 - porosification 897
- silicon microparticles 899
- SILs (self-immolative linkers) 553
 - acyclization-based 556
 - clinical application 582
- single formulation 1023
- single-chain diabodies (scDb) 105
- single-chain Fv (scFv) 452, 459
- single-photon emission computed tomography (SPECT) 805
 - radionuclide delivery 411, 415, 433
 - radiopharmaceuticals 259
 - SPECT/CT 247
 - tracers 259
 - tumor imaging 34, 35
- single-type therapy 806
- singlewalled carbon nanotube (SWNT) 896, 1165
 - biodistribution 1176
 - dispersed 1172
 - PEG-coated 1176
 - structure 35
- sinusoidal endothelium 328
- SIP (small immunoproteins) 424
- siRNA (small interfering RNA) 542, 1197, 1361
 - aptamer conjugates 1273
 - aptamer–siRNA chimeras 1379
 - hydrogel-based therapy 1085
 - ligand-assisted vascular targeting 609
 - MSV 899
 - nanoparticles 545
 - PIC micelles 1058
 - therapeutic applications 1383
- site-specific drug attachment 90
- site-specific drug delivery 1054
- site-specific PEGylation 628
- site-specific pharmaceutical carriers 951
- site-specific prodrug activation 591
- size fractionation 232
- size-dependent targetability 281
- skin keratinocytes 297
- SLN (sentinel lymph node) mapping 247
 - SPECT/CT 276
- slow-release mechanism 1341
- small immunoproteins (SIP) 424
- small interfering RNA (siRNA) 542, 1197, 1361
 - aptamer conjugates 1273
 - aptamer–siRNA chimeras 1379
 - hydrogel-based therapy 1085
 - ligand-assisted vascular targeting 609
 - MSV 899
 - nanoparticles 545
 - PIC micelles 1058
 - therapeutic applications 1383
- small molecules 1283
 - cell-penetrating 534
 - lipophilicity 1287
- small-animal hybrid scanners 249
- small-molecular-weight ligands 1382
- small-molecule delivery 1270
- small-molecule drugs 1079, 1139
- small-molecule–photosensitizer conjugates 1588, 1589
- SMANCS 65, 67, 70, 871
 - hepatotropic delivery 1543, 1555
 - postmarketing survey 1558
 - structure 872, 1544
- SMANCS/Lipiodol 77, 1558
- smart polymeric micelles 1054
- smart polymers 1074
- SMA–pirarubicin micelles 75
- SOD (superoxide dismutase) 1084
- soft-tissue sarcomas 937
- solid lipid nanoparticles 1508

- solid tumors 1391
 - accessible vascular targets 415
 - local gene delivery 1391
 - pathophysiological characteristics 65, 667
 - responsive liposomes 989
 - serum proteins 752
 - targeting 1523
 - vascular characteristics 65
- solubility 577, 840
- solution temperature
 - lower critical 668, 672
- somatostatin 269
 - receptors 1236
 - targeted cytotoxic analogs 1236
- somatostatin receptor (SSTR) 34
 - molecular imaging 270
- spacers 1283
 - carbohydrate-based 1283
 - elongated 257
 - peptide-based 1288
 - poly(ϵ -caprolactone) 257
 - self-immolative 6, 25
- SPARC (secreted protein, acidic and rich in cysteine) 782, 1135, 1323
 - nab-paclitaxel 1155
 - overexpression 1144
- specific localization 420
- specificity
 - binding 961
- specifier (trigger) 556, 564
- SPECT (single-photon emission computed tomography) 1053
 - functional and molecular imaging 249
 - radionuclide delivery 411, 415, 433
 - radiopharmaceuticals 259
 - tracers 259
 - tumor imaging 34, 35
- SPECT/CT 247
 - adrenocortical tumors 279
 - biomarkers 258
 - bone metastases 277
 - clinical applications 272
 - neuroendocrine tumors 281
 - preclinical imaging 258
 - SLN mapping 276
 - thyroid cancer 278
- Spectral Index 339
- spherical micelles 1054
- SPIO (superparamagnetic iron oxide) 56
 - active targeting 232
- SPION (superparamagnetic iron oxide nanoparticles) 44, 899
 - dendrimer-coated 270
 - hydrogel-based 1089
 - YCC-DOX 1548
- splenic macrophages 1366
- split-mix synthesis method 17
- sponge effect
 - proton 1059, 1118, 1375
- spontaneous metastasis 85
- spontaneous ring-closure
 - esters/amides 557
- Sprague-Dawley rats 693
- sprouting
 - endothelial 34
- squamous cell carcinomas (SCC) 40
- SS-PEG (succinimidyl succinate PEG) 630
- SSIP 649, 650, 1479
- SSTR (somatostatin receptor) 34, 269
 - molecular imaging 270
- stability
 - chemical 1365
- stable conjugates 871, 1287
- stable micelles 673
- staging of cancer 273
- staining 1013
 - microtubules 272
 - tissue 339
- standards
 - GMP 27
- Staudinger ligation 571
- “stealth” type liposomes 1026
- stealth effect 79
- STELLAR 859
- stem cells
 - cancer 95
- steric barrier 992
- steric hindrance
 - shRNA expression 1425
- sterically stabilized liposomes 909
 - pharmacokinetics 913
 - structure 908
- steroid hormone receptor (SHR) 261
- stimuli
 - tumor-intrinsic 994
- stimuli-sensitive polymers 668, 1074
- strategy
 - drug delivery 599
- streptavidin 34
- streptonigrin 66
- stromal fibroblasts 46
- structural and functional irregularities
 - tumor microvessels 38
- structural factors
 - macromolecules 112
- structural motif
 - branching 514

- structure
 - molecular 275
 - structure modification 1365
 - structure–activity relationship (SAR) 18
 - structure–function analysis 1014
 - subcellular fate of macromolecules 101
 - subcellular localization 1573
 - CPP-ELPs 683
 - subcellular organelles
 - pH variations 1100
 - subcellular targeting 258
 - subcellular trafficking pathways
 - nonviral vectors 1060
 - subunits
 - branched 278
 - succinate linkage 722
 - succinimidyl carbonate PEG (SC-PEG) 631
 - succinimidyl succinate PEG (SS-PEG) 630
 - sugar modification 1364
 - suicide gene therapy 1397
 - suicide substrates 566
 - sulhydryl-reactive cross-linkers 1137
 - sulfo-NHS-LC-biotin 532
 - super-stealth property 1063
 - superoxide dismutase (SOD) 1084
 - superparamagnetic iron oxide (SPIO) 56
 - active targeting 232
 - superparamagnetic iron oxide nanoparticles (SPION) 43, 899
 - dendrimer-coated 258
 - hydrogel-based 1089
 - YCC-DOX 1548
 - supportive care 6
 - suppression
 - epigenetic 1423
 - supramolecular architectures 735
 - supramolecular drug entrapment 520
 - supramolecular voids 275
 - surface charge
 - micelles 1113
 - surface functionalities
 - micelles 1113
 - surface plasmon resonance 112
 - surface stabilizing agents
 - amphipathic 1041
 - surface-grafted chains 992
 - surgery
 - imaging-guided 1062
 - survival
 - progression-free 1039, 1154
 - survival curve
 - Kaplan–Meier 1118, 1501, 1615
 - SWNT (singlewalled carbon nanotube) 896, 1165
 - biodistribution 1176
 - dispersed 1172
 - PEG-coated 1176
 - structure 1164
 - sympathetic nervous system 281
 - synergy 1099
 - endocytic release/endocytosis 1099
 - heat map 1021
 - In vitro evidence 1017
 - PUFAs/cytotoxic drugs 1331
 - ratio-dependent 1016, 1031
 - synthesis 1219
 - cytotoxic somatostatin analogs 1219
 - L-HSA 1533
 - ladder method 22
 - LHRH cytotoxic analogs 1223
 - phospholipids 250
 - polysaccharide–drug conjugates 707
 - split-mix method 17
 - synthetic glycoside clusters 1525
 - synthetic ligands 1526
 - synthetic polymers 953
 - liposome-membrane-incorporated 966
 - thermo-responsive 671
 - synthetic
 - elastin-like polypeptide 678
 - systematic evolution of ligands by exponential enrichment (SELEX) 1264, 1265, 1381
 - systemic FcRn-mediated recycling 92
 - systemic toxicity 1610
 - systems biology approach 1015
- t**
- T-cell engager
 - bispecific 464
 - T-cell response 28
 - T-cell retargeting 464
 - T-cell targeting 110
 - T-lymphocytes
 - cytotoxic 451
 - tag
 - coding 23
 - tailor-made hydrogels 1071
 - tailor-made linkers 793
 - tails 1219
 - cytoplasmic C-terminal 1219
 - hydrophilic molecular 1574
 - TandAb antibodies 469
 - tandem molecules 468
 - tandem reaction
 - retro-aldol–retro-Michael 566

- target antigen selection 295
- target cell activation
 - (un-)cleavable AMCs 389
- target cell metabolites 386
- target cell specificity 1366
- target identification
 - drugs 52
- target space
 - transvascular pumping 329
- target tissue
 - retention time in 1276
- targetability
 - size-dependent 281
- targeted cancer cells 385
 - bystander effects 388
- targeted cancer therapy 1263
- targeted cytotoxic peptide analogs 1220
- targeted cytotoxic somatostatin analogs 1236
- targeted delivery 1263
 - aptamer isolation 1263
 - aptamers 1266
 - folate receptor-mediated endocytosis 1284
- targeted diphtheria toxin 1473
- targeted imaging agents 233
- targeted kinase 1471
- targeted liposomes 1502
- targeted polymer therapeutics 599
- targeted protein toxins 1443
 - clinical trials 1443
 - combination therapy 1445, 1446
 - domains 1447
 - enzyme-related 1469
 - schematic overview 1444
- targeted radiotherapy 414, 1238
- targeted RIP variants 1475
- targeted Rnase 1470
- targeted therapy 26
 - HCC 1522
 - nanoparticles 236
 - thermo- 1272
- targeted toxins 1443
 - biological half-life 1459
 - bispecific 1443
 - clinical development 1472
 - immunogenicity 1460
 - preclinical development 1462
 - saporin-based 1456
 - tumor penetration 1461
- targeting 1053
 - active 1053, 1205, 1612
 - anticancer platinum complexes 1605
 - cell-penetrating peptides 1189
 - central nervous system 1489
 - CPPs 1202
 - dendritic polymers 513
 - drug 951
 - dual 616
 - EPR 85
 - externally activated 1001
 - folate receptor-targeted micelles 1119
 - FR-targeted immunotherapy 1298
 - immune therapy 483
 - in vivo 341
 - LHRH conjugates 1223
 - ligand-assisted vascular 591
 - liposomes 3, 967
 - liver tumors 1519
 - lung tumors 343
 - mitochondrial 260, 273
 - nanosized carriers 1523
 - organ-specific 1612
 - passive 56, 639, 1203, 1616
 - PDT 1573
 - PEGylated liposomes 910
 - peptide receptors 1219
 - pH-dependent 1205
 - photosensitizer 1569
 - polysaccharide-based drug conjugates 747
 - pop-up mechanism 1121
 - pre- 429
 - pre-antibody era 442
 - principles 34
 - protein toxins 1443
 - receptor/antigen 786
 - serum albumin 105
 - subcellular 260
 - TcRn 102
 - tissue 282
 - to T-cells 110
 - triggered cell 995
 - using transferrin 773
 - vascular 327
 - vitamin 1308
- targeting ligands 1366
 - immunoliposomes 966
 - siRNA/miRNA 1381
- targeting moieties 258
 - antibodies 1205
 - dendrimers 251
 - immunotoxins 1448
- targets 1099
 - tissue-specific 334
 - vascular 411
 - xenograft 26
- TAT (protein transduction domain) 1456
- TAT (transactivator of transcription) 1113, 1189
- TAT peptide 995

- TAT-conjugated polymeric micelle 1114
- Tat-ELP-GFLG-DOX complex 689, 692
- TAT-functionalized micelles 1121
- TATA box 1424
- taxanes 12, 909, 930, 1145
- taxoid conjugates
 - second-generation 1332, 1345
- Taxol 1142
- Taxotere 1154
- tegafur 1337
- temozolomide 830
 - astrocytomas 37
- temperature 1361
 - LCST 668, 672
 - temperature-sensitive carriers 674
 - temperature-triggered phase transition 672
- terminal modification 1365
- terminal repeats
 - inverted 1433
- testosterone level
 - serum 1086
- Tet-inducible systems 1424
- TetR 1426
- $\Delta 8$ -tetrahydrocannabinol 1134
- tetrasulfoindotricarbocyanine (TSCA) 608
 - PEG–TSCA conjugates 610
- tetravalent flexibodies 458
- Tf-CRM107 773, 788
- TfR (transferrin receptor) 960, 966
- theranostics 1062
 - CNTs 1180
 - radionuclides 435
- therapeutic agents
 - molecularly targeted 808
- therapeutic antibodies 443
 - marketed 445
- therapeutic applications 1361
 - dendrimers 545
 - siRNA/miRNA 1383
- therapeutic peptides 684
- therapeutic radionuclides 419
- therapeutic strategies
 - gene 1391
- therapeutics 805
 - APN-targeted polymer 613
 - drug-free macromolecular 267
 - personalized 16
 - polymer 263, 591, 701
 - targeted polymer 599
- therapy 805
 - adjuvant bisphosphate 805
 - antiangiogenic approved 593
 - boron neutron capture 276, 538
 - cancer 295
 - combination 1013
 - empowered antibodies 46
 - endocrine 807
 - gene 237, 1394
 - HAART 921
 - hydrogel-based 1071, 1075
 - hyperthermia 668
 - immunogene 1394
 - intra-arterial 1558
 - local ablative 1521
 - local gene delivery 1391
 - multiagent 808
 - neutron capture 539
 - PDEPT 812
 - PELT 812
 - photodynamic 278, 537, 1087, 1149, 1311
 - polymer-based combination 805
 - PRRT 272
 - radioimmunotherapy 1206
 - radionuclides 418
 - radiopeptide 271
 - response to 274
 - responsive liposomes 989
 - single-type 806
 - suicide gene 1397
 - targeted 236
 - targeted thermotherapy 1272
 - temozolomide 39
 - vectors 1398
 - viro- 1397
- thermal ablation 898
- thermal cycling
 - inverse 680
- thermo-responsive ELP carriers 692
- thermo-responsive polymers 667
 - hyperthermia treatment 670
 - synthetic 671
- thermocouple 694
- ThermoDox 1554
- thermosensitive gelation 1077
- thermostable human endopeptidase 23
- thermotherapy 1088
 - targeted 1272
- thioether bonds 258, 272
- thioether linkers
 - noncleavable 273
- thiol-binding moiety 784
- thiolation reagents 93
- thiol–disulfide exchange cleavage 379, 388
- thiophenol derivatives
 - benzyl eliminations 567
- thiophilic heterobifunctional cross-linker 1289

- thrombocytopenia
 - FNIT 91
- thymidine analogs
 - structure 256
- thymidylate synthase 1534
- thyroid cancer 278
- TICs (tumor-initiating cell) 111
- time–plasma concentration curve 891
- tissue-specific targets 1163
 - genomics approaches 335
 - identification 334
- tissues 1163
 - damage 23
 - extravasation 535
 - interactions with CNTs 1168
 - microvasculature 38
 - pH variations 1100
 - retention time in 1276
 - staining 339
 - targeting 281, 341
 - ulceration 24
- titratable groups 1103
- titratable polymers 999
- TML (trimethyl lock) 647
- TNF (tumor necrosis factor) 96
- TNF- α -expressing vector 1406
- TNF-related apoptosis-inducing ligand (TRAIL) 1454
- TNP-470 822
- α -tocopherol 1307
- toll-like receptor (TLR) 1277, 1367
- tomography
 - computed 34, 47
- topoisomerase I inhibitor 67, 817
- topotecan 928
- toxic moieties 1452
- toxic payload 34
- toxicity 1163
 - cardio- 20
 - CNTs 1170
 - dose-limiting 991, 1032
 - gastrointestinal 1037
 - general 1461
 - hepato- 21
 - liver 102
 - nephro- 22
 - systemic 1610
- toxicity profile 952
 - PEG 628
 - PEGylated liposomes 915
- toxicology 1013
 - aptamer conjugates 1013
 - GLP 1038
- toxins 1443
 - anthrax 1443, 1465
 - bacterial 1462, 1464
 - biological half-life 1459
 - delivery 1455
 - diphtheria 1448
 - mammalian 1480
 - plant 1464, 1466
 - protein 1310
 - *Pseudomonas* 13
 - targeted 1443, 1460
- tracers 1099
 - glucose analog 1099
 - labeling 262
 - PET imaging 251
 - SPECT imaging 259
- TRAIL (TNF-related apoptosis-inducing ligand) 1454
- transactivator domain
 - VP16 1425
- transactivator of transcription (TAT) 1113, 1189
 - TAT-functionalized micelles 1121
- transaminases 102
- transarterial chemoembolization 1521
- transbilayer pores 1000
- transcellular delivery
 - caveolae-mediated 1057
- transcription factors 1328
- transcriptome 49
- transcytosis 1507
 - albumin 1134
 - gp60-mediated 1324
 - paclitaxel 1140, 1141
 - sequential 85
- transdrug
 - DOX 1546, 1553
- transducers
 - HIFU 670
- transfection ability 1058
- transfection efficiency
 - electroporation 1370
- transferrin 747, 1584
 - anticancer agents 763
 - diferric 749
 - DOX conjugates 772
 - drug conjugates 772
 - radiolabeled 753
 - synthetic approaches 759
 - targeting strategies 773
 - X-ray structure 749
- transferrin cycle 750
- transferrin receptor (TfR) 960, 966
- transferrin-based therapeutics 1463

- transferrin-conjugated PEGylated liposomes
 - brain targeting 1502
- transferrin-USPIO nanoparticles 233
- transgenes 1393
- transgenic livers
 - X/myc 1548
- transillumination 1003
- translocation
 - dendrimers 535
- transmembrane glycoprotein 1309
- transmembrane pores 1000
- transmembrane sialoglycoprotein 96
- transmural coupling 43, 47
- transvascular pumping target space 329
- trastuzumab 239, 310, 933, 1151
 - biodistribution 108
- trastuzumab conjugates
 - disulfide-linked 383
- trastuzumab emtansine 384
- trastuzumab–maytansinoid conjugates 384
- treatment planning
 - radiation 275
- triacyl lipids 1580
- trials 1359
 - clinical 1343
 - phase I 1342
 - phase II/III 1343
- triblock copolymers 1061
- trigger (specifier) 556
 - elimination-based groups 564
- triggerable cell penetration 995
- triggered cell targeting 995
- triggered release 996
- trimethoxybenzylidene acetals 1112
- trimethyl lock (TML) 647
- tripartate prodrugs 556
- triple body 460
- Trojan peptides 1447
- tropoelastin 678
- TSCA (tetrasulfoindotricarbocyanine) 608
 - PEG–TSCA conjugates 610
- tube formation 35
- tumor cell-targeting phages 12
 - in vivo selection 14
- tumor extracellular pH-triggered drug release 1104
- tumor microvessels 331
 - functional irregularities 38
 - structural irregularities 38
- tumor necrosis factor (TNF) 96
- tumor suppressor protein Rb 687
- tumor targeting 1099
 - EPR 85
 - nanoparticles 16
 - passive 639
 - polysaccharide-based drug conjugates 747
 - pop-up mechanism 1121
- tumor therapy
 - responsive liposomes 989
- tumor xenografts
 - colorectal 645
- tumor-associated enzymes 249
- tumor-homing peptides 1149
- tumor-initiating cell (TICs) 111
- tumor-intrinsic stimuli
 - activation 994
- tumor-labeling markers 1192
- tumor-promoting eicosanoid biosynthesis 1326
- tumor-specific activation 564
- tumor-specific enzymes 1056
- tumor-specific receptor 1444
- tumor-targeted liposomes
 - cancer chemotherapy 955
- tumoral receptors
 - LHRH 1222
- tumorotropic accumulation 65
- tumors 951
 - ablation 951
 - acidosis 53, 55
 - adrenocortical 279
 - angiogenesis 65, 591
 - blood flow 37
 - brain 1241, 1495
 - cell cycle modulation 1198
 - cervical 42
 - chaotic microcirculation 44
 - extracellular acidity 1100
 - fluorescent probes 541
 - genetic heterogeneity 13
 - growth curve 15
 - HER2-positive 428
 - hormonally responsive 26
 - hypoxia imaging 40
 - hypoxic cell fraction 267
 - imaging 17
 - in vivo delivery studies 390
 - interstitium 41, 994
 - Lewis lung 913
 - liver 1519
 - lung 343
 - lymphangiogenesis 37
 - MDA435/LCC6 1028
 - MDR 1026
 - metabolism 65
 - microenvironment 251
 - microscopic 33

- microvasculature 38
 - murine 4
 - neuroendocrine 270, 281
 - pathophysiological microenvironment 48
 - pathophysiology 65, 667, 782
 - penetration by targeted toxins 1461
 - perfusion 46
 - pH-triggered micelles 1099
 - platinum-refractory 928
 - pretherapeutic oxygenation 268
 - primary bone 1614
 - proliferative activity 264
 - RECIST 34
 - recurrence 40
 - solid 433, 752
 - suppressor p16 1201
 - suppressor p21 1202, 1207
 - suppressor p27 1202
 - suppressor p53 1200
 - targeting 1202
 - targeting principles 34
 - types 6
 - uptake of Opaxio 842
 - vascular characteristics 65
 - vascular targeting 327
 - vascularity 37
 - vascularized 990
 - zzz 278
 - tunable dendrimers 535
 - “two-in-one” antibodies 453
 - two-phase clinical trials
 - ADEPT 25
 - TXP (DHA–paclitaxel) 1338
 - antitumor activity 1340
 - pharmacokinetics 1339
- u**
- U-PEG 633
 - U-PEG-Lys-maleimide-Fab ϵ 637
 - U-PEG-Lys-NHS linker 635
 - ulceration
 - tissue 24
 - ultra-small SPIO (USPIO) particles 227
 - ultrasound 1489
 - contrast enhanced 49
 - high-intensity focused 669, 670
 - imaging 34, 48
 - treatment 1499
 - ultrasound-activated release 1005
 - ultrasound-based heating system 669
 - uncleavable conjugates 387
 - uniformity
 - delivery 989
 - unimers 1103
 - unimolecular micelles 257
 - unspecific hydrolysis 571
 - unsymmetrical disulfide bond 1295
 - upregulation
 - proteases 554
 - uptake
 - via targeting ligands 1366
 - urinary bladder cancers
 - LHRH cytotoxic analogs 1231
 - urine M-components 934
 - uronic acid 727
 - ursodeoxycholate ligands 1614
 - US Food and Drug Administration 53
 - USPIO (ultra-small SPIO) particles 227
 - UV-activated release 1003
- v**
- V-region 444
 - vacuolization 21
 - validation 1163
 - drugs 51
 - tumor mapping 339
 - variable domains 444
 - vascular characteristics
 - solid tumors 65
 - vascular co-option 36
 - vascular endothelial cadherin 1179
 - vascular endothelial cell proteome 336
 - vascular endothelial growth factor (VEGF) 34, 539, 637
 - CPPs 1198
 - neoangiogenesis 261
 - PUFAs 1330
 - viral vectors 1416
 - vascular endothelium 327
 - vascular leakage 66
 - vascular mapping
 - historic approaches 333
 - vascular mimicry 34, 36
 - vascular modulators 79
 - vascular permeability factors 66
 - vascular side-effects 23
 - vascular targeting 327
 - ligand-assisted 591
 - vascular targets
 - mapping 411
 - vasculature 37
 - vascularized tumors 990
 - vasculogenesis 34, 36
 - vasoactive intestinal peptide (VIP) 968
 - Vectibix 453

- vector-coupled drugs 1499
 - vectorization of oligonucleotides 1196
 - vectors 1391
 - bacterial 1391
 - cancer gene therapy 1398
 - chemical 1371
 - lentiviral 1430
 - nonviral 1401
 - radionuclide delivery 1207
 - recombinant AAV 1434
 - retroviral 1428
 - TNF- α -expressing 1406
 - viral 1400, 1415
 - VEGF (vascular endothelial growth factor) 34, 539, 637
 - CPPs 1198
 - neoangiogenesis 261
 - PUFAs 1330
 - viral vectors 1416
 - VEGF receptor 261
 - vehicle control
 - PBS 468
 - vehicles
 - cyclic RGD-based 608
 - ventricular ejection fraction
 - left 918
 - venules
 - postcapillary 69
 - versatile tumor targeting 1121
 - vesicles
 - endocytic 991
 - vesicular budding and fusion 329
 - vessels 952
 - anastomosis 591
 - iliac 4
 - lymphatic 20
 - vinblastine 932
 - vincristine 917, 921, 933, 1029
 - vincristine/quercetin 1027
 - VIP (vasoactive intestinal peptide) 968
 - viral vectors 1398, 1400
 - main properties 1428
 - production 1428
 - RNAi 1419
 - shRNA delivery 1426
 - virotherapy 1397
 - virtual screening 1313
 - virus 1415
 - adeno-associated 1415, 1433
 - herpes simplex 1397, 1402
 - measles 1404
 - nonenveloped 1433
 - replication 1432
 - virus-mimetic cross-linked micelles 1122
 - vitamin B12-binding proteins 1300
 - vitamin B9 1284
 - vitamin E 1331
 - vitamin repositioning 1122
 - vitamin targeting 1308
 - vitamin–drug conjugates 1283
 - voids
 - supramolecular 275
 - von Hippel-Lindau protein 65
 - VP16 transactivator domain 1425
- W**
- wafers
 - Gliadel 1479
 - water solubility 577
 - water-soluble conjugates 1298
 - water-soluble dendrimers 579
 - water-soluble polymer–drug conjugates 272
 - Watson–Crick base pairing 1415
 - weight
 - molecular 108
 - western analysis 339
 - window chamber model 76
 - wortmannin 821, 822
- X**
- X-ray tomography
 - SPECT/CT and PET/CT 247
 - X-rays
 - CT 34
 - X-rhodamine 249
 - X/myc transgenic livers 1548
 - Xeloda 860
 - xenobiotics
 - brain targeting 1492
 - xenograft models 3, 12
 - Capan-1 human pancreatic tumor 1034
 - xenograft targets 26
 - xenografts 1359
 - A121 ovarian tumor 1348
 - B-lymphoma 103
 - CFPAC-1 1348
 - colorectal tumor 645
 - H460 human tumor 1349
 - ovarian tumor 1467
 - P-gp+ DLD1 human colon tumor 1346
 - Panc-1 pancreatic tumor 1348
 - pH 1101
 - xerostomia 25
 - XMT-1001 865, 866
 - xyloglucan–drug conjugates 734
 - xzy confocal microscopy 1378

γ

YCC-DOX 1548

YEE(GalNAcAH)₃ 1525

YILIHRN 250, 272

ylides

– azomethine 1166

Yoshida sarcoma 54

z

zoledronic acid 807

zonula occludens (ZO) 1492

zwitterions 56

– amino acid residue 76

